Genetic Epidemiology of Amyotrophic Lateral Sclerosis by Majoor-Krakauer, D.F. (Danielle)

Genetic Epidemiology of Amyotrophic 
Lateral Sclerosis
Genetische epidemiologie van 
amyotrofische lateraal sclerose
Danielle Fanny Majoor-Krakauer
© Danielle Fanny Majoor-Krakauer, 2005
No part of this book may be reproduced, stored in a retrieval system or transmitted in any form or by any means 
without permission of the author. The copyright of the publications remains with the publishers.
ISBN: 90-9019289-1
ACKNOWLEDGEMENT
The study presented in this thesis was conducted at the Neurological Institute, Columbia University Medical 
Center and the G.H. Sergievsky Center and Department of Epidemiology, Mailman School of Public Health, 
Columbia University, New York, NY, USA. 
The work was completed at the department of Clinical Genetics at the Erasmus Medical Center in Rotterdam in 
close collaboration with the Department of Epidemiology and Biostastitics of the Erasmus Medical Center.
The study was supported by a grant of the Muscular Dystrophy Association.
Cover and graphical support: T. de Vries Lentsch
Printing: Offsetdrukkerij Haveka B.V., Alblasserdam
Cover: Victor Levasseur “Oceanie”. Paris. 1854. Map shows the Pacific Ocean divided into four regions. 1. 
Malaisie, 2. Melanesie or Australia, 3. Polynesia and 4. Micronesie. These four divisions were based upon the 
surveys taken by Capt. Dumont D’Urville during his two circumnavigations in 1822-1825 and 1826-1829 during 
which he charted the Pacific Islands in great detail. Victor Levasseur, the author of this map, employed a famous 
French artist, Raimond Bonheur, to draw the wonderful & fanciful scenes surrounding the map including the 
entrance to a harbor depicted in lower right showing a fort high on a bluff and sailing vessels below. From 
Levasseur’s “Atlas National Illustre”, published in 1854.
Genetic Epidemiology of Amyotrophic 
Lateral Sclerosis
Genetische epidemiologie van amyotrofische 
lateraal sclerose
Thesis to obtain the degree of Doctor from the Erasmus University 
Rotterdam by command of the rector magnificus
Prof.dr. S.W.J. Lamberts
and according to the decision of the Doctorate Board. 
The public defence shall be held on
Wednesday  May 18  2005  at 15.45 hrs by
Danielle Fanny Majoor-Krakauer
born in The Hague
Promotiecommissie
Promotoren
Prof.dr. H. Galjaard
Prof.dr. A. Hofman
Overige leden
Prof.dr. R. Ottman
Dr. J.C. van Swieten
Prof.dr. J.H.J. Wokke
CONTENTS
9 CHAPTER 1
SCOPE OF THE THESIS
13 CHAPTER 2
AMYOTROPHIC LATERAL SCLEROSIS
AND ASSOCIATED DEMENTIA AND PARKINONISM
29 CHAPTER 3
THE GENETIC EPIDEMIOLOGY
OF AMYOTROPHIC LATERAL SCLEROSIS
Review: Clinical Genetics 2003;63:83-1001 
29 Epidemiology
32 Environmental risk factors
32 Genetic risk factors
33 Major genes
40 Susceptibility genes
45 ALS: a multifactorial disease
45 Gene-gene and gene-environment interaction
in amyotrophic lateral sclerosis
47 ALS: an unifying hypothesis
61 CHAPTER 4
A SHARED GENETIC SUSCEPTIBILITY TO AMYOTROPHIC LATERAL 
SCLEROSIS, DEMENTIA AND PARKINSONISM
63 4.1 Familial aggregation of amyotrophic lateral sclerosis, dementia and 
parkinsonism
Neurology 1994;44:1872-77
77 4.2 Increased co-occurrence of dementia and parkinsonism in the families of 
amyotrophic lateral sclerosis patients
83 CHAPTER 5
ENVIRONMENTAL RISK FACTORS
FOR AMYOTROPHIC LATERAL SCLEROSIS
85 5.1 Amyotrophic lateral sclerosis on Guam
93 5.2 A link between amyotrophic lateral sclerosis and short residence on Guam
Neurology: in press
97 5.3 Environmental risk factors and gene –environment interaction in amyotrophic 
lateral sclerosis
115 CHAPTER 6
GENERAL DISCUSSION 
115 Introduction
116 Methodology
118 Genetic associations between amyotrophic lateral sclerosis, dementia and 
parkinsonism
126 Environmental risks factors for amyotrophic lateral sclerosis
128 Suggestions for genetic counselling
129 Future perspectives
137
141
CHAPTER 7
SUMMARY
SAMENVATTING
145 PUBLICATIONS
149 CURRICULUM VITAE
151 APPENDIX
QUESTIONAIRE
CHAPTER 1
The scope of this thesis
Disease is very old, and nothing about it has changed. It is we who 
change, as we learn to recognize what was formerly imperceptible.
Charcot

9Amyotrophic lateral sclerosis (ALS), dementia and parkinsonism have in common the 
decrease in nervous system functionality due to loss of neurons through shared or discrete 
mechanisms. Although the complex etiologies of each of these disorders are not yet fully 
understood, evidence is increasing that these three neurodegenerative disorders may 
share distinct neurodegenerative pathways leading to overlapping clinical features and 
neuropathological characteristics. 
The discovery of endemic amyotrophic lateral sclerosis (ALS) in the native Chamorro 
population of the pacific island Guam in the 1950’s, its familial occurrence and the co-
occurrence of dementia and parkinsonism led to searches for environmental and genetic 
causes for these three major neurodegenerative disorders of old age. 1, 2
In this thesis we describe an epidemiological approach to search for a genetic link between 
ALS, dementia and parkinsonism in a large group of ALS patients in the New York area. 
We also studied environmental risk factors that may interact with a genetic susceptibility 
for ALS. 
After an introduction in Chapter 2, we present in Chapter 3 a review of the descriptive 
epidemiology of ALS and a classification for the major genetic causes of familial ALS 
and for the genes potentially contributing to the etiology of sporadic ALS, so-called 
susceptibility genes. 
In a case-control study conducted from 1989 to 1991 at the Neurologic Institute of 
Columbia Presbyterian Medical Center in New York, we collected structured information 
from the family histories of 151 ALS patients and 140 controls on ALS, dementia and 
parkinsonism in parents, siblings, and grandparents. 
In the first part of this thesis we present the results of the genetic epidemiologic study of 
familial aggregation of ALS, dementia and parkinsonism. Section 4.1 deals with the results 
of the analysis of the cumulative incidence of dementia in the relatives of ALS patients and 
controls and the analysis of the cumulative incidence of parkinsonism in the relatives of 
ALS patients and controls. In section 4.2 we evaluate the co-occurrence of dementia and 
parkinsonism in the families of ALS patients and controls.
The second part of this thesis deals with putative environmental and lifestyle factors 
CHAPTER 1
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related to the disease. The case control study described in 5.2 was based on the observation 
of high incidence of ALS and co-occurrence with parkinsonism and dementia in the 
native population of the pacific island Guam, as described in 5.1. We found evidence that 
residence on the pacific island of Guam, during the period of endemic ALS, is - even after 
decades- a risk factor for ALS in citizens of the Unites States.
In the case control study described in chapter 4 we also collected information on medical 
histories (specific infectious diseases, diabetes, autoimmune disorders, surgery and 
injuries), exposure to animals or to specific environmental toxins (pesticides, aluminum, 
lead and others), occupational histories, smoking habits and the consumption of alcoholic 
beverages. The role of each of these exposures was tested in univariable analyses. Further 
multivariable analysis of a preselection of exposures aimed to control for confounding. 
We investigated the interaction of specific environmental exposures with a genetic 
susceptibility to neurodegeneration by analyzing the interactive effect of each of the 
alleged environmental risk factors with a family history of ALS, dementia or parkinsonism. 
The results of this case control study are summarized in section 5.3. Methodologic issues 
and a discussion of the results of the epidemiological analyses described in this thesis are 
presented in chapter 6. 
During the past decade molecular genetic studies revealed more and more genes involved 
in mendelian inherited forms of ALS, Alzheimer’s dementia, frontotemporal dementia, 
and parkinsonism. Some of these genetic defects are associated with overlapping clinical 
and neuropathological features of ALS, dementia and parkinsonism. Furthermore, genetic 
susceptibilities have also been associated with sporadic ALS but these seem to have smaller 
effects than the genetic defects in familial ALS and are likely to interact with each other 
and with environmental risk factors to modulate susceptibility and/or disease phenotype. 
At the end of chapter 6 we offer suggestions for genetic counselling of ALS patients 
and their families. We conclude with recommendations for further delineation of the 
neurodegenerative disorders with overlapping features of ALS, dementia and parkinsonism 
and present our expectations for future research in the complex field of gene-environment 
interaction studies.
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“Six mois, un an après début, tous les symptômes se son accumulés et  plus
ou moins fortement accentués. La mort arrive au bout de deux ou trois ans en
moyenne par le fait des symptômes bulbaires.”
Charcot (in his lecture summarizing his observations concerning the disease which he called amyotrophic lateral 
sclerosis; May 18, 1874.)
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CHAPTER 2
Amyotrophic lateral sclerosis and 
associated dementia and parkinsonism
Amyotrophic lateral sclerosis, dementia and parkinsonism are generally viewed as “age-
related” (ie, occurring within a specific age range) rather than “ageing-related” disorders 
(that is, caused by the ageing process itself). 1 Amyotrophic lateral sclerosis generally 
occurs at a younger age than parkinsonism or dementia. The age-specific prevalence 
of ALS worldwide (33 per 100 000) is observed at 60 to 75 years. ALS is worldwide 
responsible for approximately 1 in every 800 deaths, of these less than 10% occur before 40 
years of age. 2-5
The prevalence of Parkinson’s disease in industrialized countries is estimated at 0.3% of 
the general population overall and about 1% in the population older than 60 years and 3.5% 
in those aged above 85 years. 6, 7 
Dementia is the most common neurodegenerative disorder, affecting about 5% of the 
population over age 65 years with a lower rate in some ethnic populations. 8, 9 Dementia 
occurs approximately in 1.5% of individuals at age 65 and prevalence doubles every 4 
years to 40% in those 95 years and older.10 The expected increase of the aged in a growing 
number of countries, of exposures to a broad range of environmental agents, and improved 
disease recognition, either at diagnosis or at death, is associated by a rise in the prevalence 
of neurodegenerative disorders. 11, 12 
 It is of great importance to elucidate the molecular pathogenesis of neurodegeneration, 
because treatment will increasingly be based on the understanding of the pathophysiology.
Amyotrophic lateral sclerosis (ALS) belongs to a class of disorders known as motor neuron 
diseases. Motor neurons arise from the motor cortex and extend from the brain stem 
throughout the spinal cord, forming the pathway to control voluntary movement. (figure 1) 
Upper motor neurons carry impulses to lower motor neurons and those innervate muscles. 
Motor neuron axons are amongst the most unusual cells in the body because of their very 
large size and their role as the critical link between the motor areas of the brain and the 
muscles. The loss of these motor neurons causes the muscles under their control to weaken 
and waste away, leading to paralysis. 
14
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Amyotrophic lateral slcerosis was first accurately described in 1874 by the famous Jean-
Marie Charcot (see picture on page 11), at the hospital La Salpêtrière in Paris, who deduced 
the relationship between the clinical signs and the findings at autopsy. “Amyotrophic” 
refers to the muscle wasting that signifies disease of the lower motor neurons. “Lateral 
sclerosis” refers to the hardness to palpation of the lateral columns of the spinal cord in 
autopsy specimens, where gliosis follows degeneration of the corticospinal tracts. In North 
America the term “ALS” is used interchangeably with “Lou Gehrig’s disease” in memory 
of the famous baseball player who died of this disease in 1941. (figure 2) In Britain the 
term “motor neurone disease” referring to the degeneration of the upper and lower motor 
neurons, is applied. 13
Figure 1. The human motor neuron system
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Figure 2. Lou Gehrig
A considerable increase in mortality from ALS has been observed in the last three decades 
in Western nations. 14-17 The most significant factor in the geographical variation of ALS 
mortality is the life expectancy of the populations; the higher the life expectancy of the 
population concerned the higher the mortality rate of ALS. The rise of ALS paradoxically 
occurs precisely because populations have overall become healthier and thus more 
individuals are living up to the ages at which ALS is expressed. 18
Clinical features of amyotrophic lateral sclerosis
The characteristic feature of amyotrophic lateral sclerosis is the rapidly progressive muscle 
weakness without sensory signs leading to limb weakness. ALS usually begins in the fifth 
and sixth decades of life. At onset fatigue, cramps, muscle weakness and wasting of one 
or more limbs or fasciculation of the tongue (bulbar onset) occur. 19, 20 Bulbar involvement 
causes difficulties in swallowing and respiration, and is a frequent cause of death in later 
stages of disease. In a typical patient, the muscles that control eye movement, bowel and 
bladder function are spared. Features that arise from dysfunction of the upper motor neuron 
are spasticity, and brisk tendon reflexes (like the extensor plantar responses, Babinski 
sign). Loss of lower motor neuron results in muscle weakness, painful cramps and muscle 
fasciculations followed by muscle atrophy and loss of tendon reflexes. When loss of both 
upper and lower motor neurons occurs spasticity or weakness may predominate before 
the amyotrophy develops. Pathologically increased reflexes are more common than loss of 
reflexes. 21
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The prognosis of classic ALS is grave, with death occurring in three to five years after 
onset of symptoms. However, 10 to 20% of the patients have a milder variant of ALS and 
may survive for more than 10 years. 22 Prediction of progression and survival is difficult but 
might be associated with the site of initial clinical involvement and the patient’s age at the 
time of disease onset. Patients in whom bulbar symptoms occur first are considered to have 
shorter survival times. 23-26 
Currently there is no cure for ALS, the available therapy may prolong survival only. The 
relentless course is a great burden to patients, relatives and caregivers.
Clinical diagnosis of ALS depends traditionally on signs of progressive limb, bulbar, or 
respiratory muscle weakness and the physical signs of upper and lower motor neuron 
deficits. Essential investigations include imaging of the spinal cord, and sometimes 
brain, to exclude compressive or inflammatory lesions. 21, 27 Currently the El-Escorial 
World Federation of Neurology Criteria and its more recently revised version, the Airlie 
House Criteria, are used internationally for the diagnosis of ALS. These criteria grade 
the likelihood of ALS according to the number of bodily regions involved from clinical 
examination and electromyography, and require upper and lower motor neuron loss with 
progression of signs within a body region and to other body regions. 28-30
According to the El Escorial criteria, ALS, combined with other neurological disorders, 
such as dementia and parkinsonism, is defined as ALS plus. Electrodiagnostic examination 
is also important in the diagnosis of ALS. Nerve conduction studies are necessary to 
exclude conductions block, and electromyography to confirm muscle denervation. 31, 32
Familial amyotrophic lateral sclerosis
Familial forms with Mendelian inherited ALS are observed in approximately 5 to 10 
percent of the patients and are clinically and neuropathologically indistinguishable from 
sporadic ALS. Genetic analyses over the last decade have identified seven autosomal 
dominant and three recessively inherited forms of ALS (see Chapter 3 page 34 , table 
and Chapter 6, page 124 table). Sporadic ALS has been associated with ‘susceptibility’ 
genes because the neurodegenerative effect of these genetic changes probably depends on 
interactions with other prevalent, low penetrant genetic defects and/or with environmental 
risk factors (see Chapter 3 page 34 , table). 
As more genetic defects are identified it becomes more and more clear that ALS 
phenotypes are part of a broader disease spectrum. Generally, the recessive forms, ALS2 
and ALS5, have a juvenile onset, with slow progression and a prolonged survival of many 
decades. 33-35Adult onset of disease with a survival of more than ten years belongs to 
the clinical features of the recessive form of ALS1. 36-40 The broad clinical spectrum of 
dominant inherited forms, ALS4, ALS6 and ALS8, may also include prolonged survival. 
In ALS4, mutations of the senataxin gene (SETX) gene cause a form of ALS featuring 
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juvenile onset, slowly progressive symmetrical distal limb weakness and amyotrophy 
combined with pyramidal signs without bulbar involvement. 41-43 The mechanism 
underlying the clinical variability caused by one mutation in the vesicle trafficing protein 
(VAPB) gene in ALS8 is still unclear. ALS8 is associated with the broad spectrum of 
clinical features including rapidly progressive adult onset ALS with or without tremor and 
adult onset spinal muscular atrophy without pyramidal or bulbar signs. 44 
Amyotrophic lateral sclerosis and dementia 
Dementia is a prominent feature of ALS. It has been suggested that cognitive decline 
and/or cortical degeneration occurs in as much as half of the ALS patients. 45, 46 Over the 
past decade the clinical pattern of ALS-associated dementia has been better delineated, 
with help of neuropsychological testing, imaging studies, and neuropathological data. 
The cognitive impairment can precede, accompany, or follow the features of ALS. 
Psychometric testing has characterized the type of cognitive impairment in most ALS 
cases as being frontal lobe or frontotemporal lobe type. 23, 47-59
Familial ALS with dementia occurs in ALS1, ALS6, the ALS-dementia complex 
mapped to a locus on chromosome 9q21-22, and in a growing number of families with 
genetic syndromes with or without parkinsonism. 60-63 Similarly, co-morbidity of ALS 
and parkinsonism, together with neuropathological and neuroimaging evidence of 
dopaminergic deficit in sporadic and familial ALS patients suggests related or overlapping 
neuropathologic pathways. 64-68 69
The features in ALS patients with dementia and/or parkinsonism may bear clinical 
similarity to ALS, locally called ‘lytico’, and the parkinsonism-dementia complex, called 
‘bodig’, on the Pacific island Guam. A well-known characteristic of these disorders is the 
intrafamilial variability of the phenotype. 70-75 Within a pedigree, family members can 
present with different clinical symptoms, which may reflect variation in the distribution 
and severity of the pathologic process. 
Advances in molecular genetic research have delineated several familial forms of ALS 
with progressive frontal lobe dementia (FTD). One of these forms is the autosomal 
dominant complex of ALS, FTD and/or parkinsonism, associated with mutations in 
the tau gene. This disorder is referred to as FTDP-17 (because the tau gene is located 
on chromosome 17). Most of the chromosome 17-linked families were found to have 
disease-causing mutations in the microtubule binding domain coding, mostly associated 
with overexpression of the 4 repeat isoform of the tau protein, or in splicing regulatory 
sequences of the tau gene. 70, 71, 76 77, 78 Tau proteins are a group of microtubule associated 
proteins that play an important role in promoting the assembly and maintaining the 
structure of microtubules. They are expressed in neurons being particularly abundant 
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in axons. Alternate mRNA splicing of exons 2,3, and 10 of the tau gene results in the 
expression of six isoforms in the nervous system. The predominant isoforms differ by the 
presence of either 3 or 4 repeat domains, which results from the exclusion or inclusion of 
exon 10. Filamentous deposits made of tau constitute a major defining characteristic of 
several neurodegenerative disorders known as tauopathies. Some of the tauopathies are 
caused by mutations or polymorphisms in the tau gene.79 Among the various forms of 
frontotemporal dementia (FTD) approximately 50% of familial FTD is caused by mutations 
in the tau-gene. 80-83 Tauopathies do not seem to play an important role in the clinico-
pathological spectrum of ALS-FTD. 49, 82, 84-88
The occurrence of both major features of Alzheimer pathology, extracellular cerebral 
amyloid plaques and intraneuronal neurofibrillary tangles is rare in ALS and
ALS-dementia. However, plaques without neurofibrillary tangles are known to occur in 
ALS-dementia. 89 And the hallmark of Guamanian ALS/PDC is abundant neurofibrillary 
tangles in widespread regions of the central nervous system. 90 These tangles are composed 
of abnormally modified tau, neurofilaments and other cytoskeleton proteins. 91 
The neurofibrillary tangles in ALS/PDC exhibit very similar biochemical and 
ultrastructural properties of hyperphosphorylated tau protein and neurofilaments, to 
Alzheimer’s disease but the specific laminar and regional cortical distribution of the 
neurofibrillary tangles is different from that seen in Alzheimer’s disease. Also different 
is the absence of extracellular plaques. 92-94 The aberrant biochemical processes that 
hyperphosphorylate normal tau and/or neurofilaments into abnormal filaments in ALS, 
Alzheimers’s disease and ALS/PDC, Guadeloupean parkinsomism complex, and a form of 
familial FTD linked to chromsome 3 (or in other tauopathies without mutations of the tau 
gene) are not understood. 71, 73, 83, 85, 95-97
More and more evidence is found that tau pathology also plays a role in forms of 
parkinsonism. 81, 98-102
Ubiquitin-positive inclusions seem to be the most important common neuropathologic 
feature of sporadic and familial ALS, ALS-FTD, primary lateral sclerosis with FTD, and 
also in sporadic and some familial forms of FTD without tau gene mutations. 41, 55, 96, 103, 104 
These ubiquitin containing inclusions are negative for α- synuclein or tau. 105-108  The most 
specific ubiquinated inclusions in ALS, the Bunina bodies, occur in the majority of patients 
with uncomplicated ALS, ALS/PDC, ALS-FTD, and ALS without clinical signs of FTD or 
parkinsonism despite frontotemporal atrophy and degeneration of the substantia nigra. 73, 109
The similarities in the molecular pathology of ubiquitinated inclusion bodies in ALS, 
ALS/FTD with or without parkinsonism, and some forms of familial FTD, strongly suggest 
related disorders that belong to a clinicopathological spectrum. 49, 105, 109-114 96 
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Marked differences in the anatomical distribution of lesions determine the predominance 
and type of motor and cognitive features in each syndrome. 49, 115
Amyotrophic lateral sclerosis and parkinsonism
Although the association with parkinsonism may be less apparent than with dementia, 
post-mortem examination of patients with ALS confirms that the neurodegenerative 
process may extend from the frontotemporal cortex to the basal ganglia. 49, 116 Parkinson’s 
disease is characterized by resting tremor (classically resembling pill rolling), rigidity, 
and bradykinesia, which typically responds to dopamine treatment. The neuropathologic 
hallmarks are loss of dopaminergic neurons and depositions of cytoplasmatic protein 
aggregates termed Lewy bodies in the sustantia nigra. Lewy bodies are composed of 
numerous proteins, including α-synuclein, neurofilaments, and ubiquitin. 117 The movement 
disorder in Parkinson’s disease is thought to arise from reduced dopaminergic input to 
the striatum as a result of nigral degeneration. Parkinsonism is a clinical syndrome with 
features resembling those of Parkinson’s disease, is distinguished from the latter by the 
presence of additional clinical and neuropathological features. About 15% of patients have 
first- degree relatives with the disease, typically without a clear mode of inheritance. 118, 
119 The main etiology in Parkinson’s disease is complex and seems to be determined by 
several genetic as well as non-genetic factors. 120 In the last few years molecular genetic 
analysis led to the identification or localisation of eleven loci for rare autosomal dominant 
and recessive inherited forms of parkinsonism. 121, 122 Missense mutations, duplication 
and triplication of the α-synuclein gene cause autosomal dominant familial disease. 123, 
124 Dementia is observed in patients with the triplication of the α-synuclein gene. 125, 126 
Α-synuclein is a major constituent of Lewy bodies. The mutations and the dose-effect 
of the α-synuclein gene provide a direct link to the neuropathology, suggesting that α-
synuclein deposition is relevant to the degeneration of nigral neurons. 126 Moreover linkage 
of synuclein and tau pathology has been observed in patients with distinct α-synuclein 
mutations and in ALS/PDC patients on Guam, suggesting synergistic interaction that 
accelerates fibrillization of both proteins. 98, 127
Mutations in the parkin, DJ-1 and PINK1 genes cause autosomal recessive inheritance 
of parkinsonian disorders. 128-130 Parkin-linked cases (PARK2) generally exhibit selective 
loss of nigral degeneration in absence of Lewy bodies, even though the clinical features of 
patients bearing parkin mutations are often indistinguishable from idiopathic Parkinson’s 
disease. 131, 132 Parkin is an E3 ubiquitin ligase , targeting and promoting degradation of α-
synuclein. The absence of Lewy bodies in PARK2 shows that parkin loss of function may 
cause degeneration by a mechanism other than aberrant protein accumulation. 121, 133, 134 
The most recent identified and the most frequent cause of familial parkinsonism (PARK8) 
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is associated with mutations in the LRRK2 gene, coding for the dardarin protein (from 
the Basque word dardara, which means tremor, referring to the Basque origin of the first 
affected families). 135 In PARK8 patients a wide spectrum of nigral pathology is found: 
absence of other distinctive pathologic features (‘pure nigral degeneration’); brainstem 
Lewy bodies, typical of Parkinson’s disease; widespread brainstem and cortical Lewy 
bodies, consistent with Lewy Body dementia; or absence of Lewy bodies but presence 
of neurobibrillary tangles, consistent with a tauopathy like FTDP-17. 63, 69, 135-138 Clinical 
features of PARK8 includes parkinsonism with dementia or amyotrophy or both, 
suggesting that the function of the LRRK2 gene may be central to the pathogenesis of 
several major neurodegenerative disorders associated with parkinsonism. 69 
Thus, the clinical, pathological, and genetic heterogeneity associated with familial ALS, 
dementia and parkinsonism suggest that multiple pathogenetic events may result in 
neurodegeneration, which may produce variably ALS, dementia and/or parkinsonism, 
along with variable pathologic features. A central challenge for research will be to identify 
these multiple pathogenic mechanisms and their points of molecular convergence.
With the current study we aimed to find support for a shared genetic susceptibility to the 
three major neurodenegerative disorders, dementia, parkinsonism and ALS. In that view, 
new genetic studies should be directed at finding genetic defects in families presenting with 
familial aggregation of these three disorders. This approach might become as successful as 
the genetic research in families with either one of these disorders. Indeed, the results of the 
genetic studies of either one the disorders more and more point in the direction of genetic 
causes for overlapping neurological phenotypes. 
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The genetic epidemiology of ALS
Introduction
Amyotrophic lateral sclerosis (ALS) is a late onset, rapidly progressive and ultimately 
fatal neurological disorder. The disease, also referred to as motor neuron disease or Lou 
Gehrigs disease, is caused by a progressive loss of motor neurons in the brain and spinal 
cord. It usually begins focally and then spreads. There is concurrent involvement of 
corticospinal (upper) and spinal (lower) motor neurons. The diagnosis is based on the El 
Escorial criteria.1 Involvement of the lower motor neurons results in muscle denervation of 
the affected muscles, loss of tendon reflexes and fasciculations, followed by muscle atrophy. 
Degeneration of corticospinal motor neurons causes additional focal spasticity. Clinical 
experience indicates that before spreading the disease begins with fatigue, cramp, muscle 
weakness and wasting of one or more limbs or fasciculation of the tongue (bulbar onset). 
Losses of reflexes are less common symptoms than pathologically increased reflexes.2 The 
disease progresses for an average of 3-5 years, leading to paralysis and premature death. 
Massive conglomeration of neurofilaments in motor neurons is observed in both familial 
and sporadic ALS. Animal studies have shown that motor neuron dysfunction precedes the 
onset of symptoms and that compensatory mechanisms are successful in maintaining motor 
functions until more than 50% of motor units have been lost, at which point symptoms 
appear and the number of motor units declines rapidly.3, 4 The progressive proportional 
increase of the aged in many populations will be associated by an increase of age-related 
diseases such as ALS. 5-8 Despite more than a century of research, there is currently no cure 
and the available therapy may prolong survival only by a few months. Familial forms of the 
disease occur in approximately ten percent of the patients. Three genes and linkage to four 
additional gene loci have been identified so far for monogenic ALS. The majority of the 
patients however have multifactorial ALS which are likely to be due to complex interaction 
between genes and environmental factors. This review focuses on the genetic background 
of ALS. 
Epidemiology
The crude prevalence of ALS is estimated at 4-6 per 100,000 population. The prevalence 
of ALS increases with age, reaching a peak in the 60-75 age group at 33 per 100,000 
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population for men and 14 per 100,000 population for women (figure 1).9-11 On average, 
a male preponderance of 1.5 to 1 is reported worldwide, but this is less pronounced 
after the age of 70 years. Male preponderance occurs only in sporadic ALS and is still 
unexplained.12, 13 The incidence rate of ALS is 1-3 per 100,000 person years and increases 
with age.9, 10, 14 A peak incidence rate is observed in the 60-75-age group of 10.5 and 7.4 
per 100.000 men and women, respectively (figure 2). Ethnicity data from the U.S. show 
lower mortality rates from ALS in nonwhites than whites (ratio of 1:1.6), but with age 
and sex differences similar to whites.15 There is a latitude-related increase in ALS, with 
geographical age adjusted incidence rates ranging from 2 in Israel (320) to 8 in the northern 
Scandinavian countries (>600).16-19 Geographical differences of ALS world-wide are 
probably the result of regional differences in ascertainment, regional differences in genetic 
susceptibility and/or exposure to environmental factors.
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Figure1. Age-specific prevalence of amyotrophic lateral sclerosis (ALS) in men and women from Harris County, 
Texas(9) and Ireland (10).
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Figure 2. Age-specific incidence of amyotrophic lateral sclerosis (ALS) in men and women for Washington State 
(14), Harris County, Texas (9) and Ireland (10).
Four well studied geographical areas with a high prevalence of ALS (clusters) are known. 
In the Chamorro population of the western Pacific islands Guam and Rota two neurologic 
conditions are frequent: ALS, locally known as ‘lytico’, and the parkinsonism-dementia 
complex (PDC) of Guam, locally known as ‘bodig’. Lytico and bodig may co-occur in 
patients and families.20 The strong suspicion of an identical aetiology has not been proven.21 
The crude prevalence rate of ALS on Guam declined from 100 in the 1950’s to 50 and 
25 per 100.000 population for men and women, respectively, in the 90’ies.22-24 Two areas 
of the Japanese Kii peninsula show a similarly high prevalence of ALS, 25,26 as well as a 
population of the western coast of Papoea New Guinea, Irian Jaya (Indonesia).27 At the 
same pacific latitude, a fourth high incidence area is found in an isolated tribe at Anguru 
on Groote Eylandt in the Gulf of Carpentaria (North Australia).28 In these endemic areas 
in the South Pacific, ALS accounts for about one in ten deaths. Also in Guadeloupe, in 
the French West Indies, an unusual high frequency of atypical parkinsonism occasionally 
accompagnied by ALS occurs, reminiscent of the one described in Guam.147 
Smaller clusters of ALS, related to professional or residential proximity, have been reported 
from the same apartment building (n=3) 30, a school (n=3) 31, a group of farm-rangers 
in South-Dakota (n=4)32, 33 105, among mail carriers (n=3) in a small town 34 or a small 
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community (6 cases of ALS between 1975 and 1983) near lake Michigan, Wisconsin, 
USA.35, 36 Conjugal ALS has been reported not only in Guam,37 but also in four couples 
outside the Western Pacific.38-41 These clusters of ALS may have been caused by common 
exposure or transmission of a causal agent, or alternatively may reflect coincidence. 
Analysis of small clusters is usually complicated because of lack of data on the total 
population of origin. Nevertheless, these clusters kept the discussion alive about potential 
environmental and genetic causes of ALS. 
Environmental risk factors
The environmental risk factors of neurodegeneration in ALS were largely unknown until 
recently. The endemic occurrence of ALS such as in the high-risk areas in the Pacific, 
could not be fully explained by genetic factors,29,42, 43 and evoked an animated discussion 
on gene-environment interaction. Cycad nuts, mineral content of the drinking water and 
the soil content became suspected as long-term acting environmental neurotoxic risks. 
Attention especially focused on the fruits of the locally growing cycad palms, as vividly 
described by Oliver Sacks in ’Cycad Island ’,44-47 also because geographical incidence rates 
for ALS are strongly correlated with concentrations of cycasin in traditional food prepared 
from the toxic seed of the cycad plants.24, 45 The pathogenic effect of cycasin seems to 
be due to a decrease of neuronal DNA-repair, persistent upregulation of tau mRNA 
expression, and enhancement of excitatory neurotoxicity.48 
Other putative environmental risk factors for ALS include a history of trauma to the brain 
and spinal cord, strenuous physical activity, and exposure to radiation, electrical shocks, 
welding or soldering materials, paint- or petroleum industry and the dairy industry. 
However, none of the exogenous risk factors for ALS has been reported consistently. 
Although malignancies were reported in 10% of patients with motor neuron disease in a 
population study,49 this association remains unexplained. Long-latency viral infections 
are another potential etiology of ALS.50, 51 Enterovirus nucleic acids have been detected 
by reverse transcriptase-PCR in 15/ 17 spinal cords of sporadic ALS patients in a French 
study, but not in more than 20 spinal cords examined in other studies.52-56
In conclusion, exogenous risk factors are inconsistently reported in ALS. This might 
indicate that these risk factors do as such not cause the pathology. Alternatively, it might 
reflect a complex interaction between several environmental factors and specific genetic 
susceptibilities. 
Genetic risk factors
Genetic risk factors for ALS have been studied extensively. Familial aggregation of ALS, 
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with an age-dependent but high penetrance, is a major risk factor for ALS. Familial ALS 
(FALS) is clinically and genetically heterogeneous with multiple autosomal dominant and 
recessive forms. Molecular genetic analysis of FALS has led to the discovery of several 
genes involved in ALS (table 1). These ALS genes, which we will refer to as ‘major genes’ 
cause ALS with a clearly monogenic inheritance pattern. They may either predominantly 
lead to ALS (ALS1-ALS6) or cause multisystem neurodegeneration (tauopathies and ALS 
with dementia and parkinsonism) with ALS as an occasional symptom. 
Other genes, that we will call ‘susceptibility genes’, may trigger the cascade of 
neurodegeneration or may act as susceptibility factors for neurodegeneration in interaction 
with environmental risk factors or other (genetic) risk factors.
This review presents a tentative classification of the “major” and “susceptibility” genes for 
ALS. Subsequently we will discuss current insights in gene-gene and gene-environment 
interaction in ALS.
Major genes
In this review, we first discuss the monogenic forms of ALS showing clear mendelian 
inheritance. Seven different gene loci for familial ALS (FALS) have been reported, and 
three major genes (SOD1, alsin and tau) have been identified (Table 1). 
The difficulty of clinically distinguishing ALS from other forms of motor neuron disorders, 
especially in patients who lack the classical signs of each disease, is underscored by the 
occasional finding of a deletion in one of the genes for spinal muscular atrophy, the survival 
motor neuron gene SMN157 and the centromeric SMN2 58, and the neuronal apoptosis 
inhibitory protein gene NAIP in patients diagnosed with sporadic and familial ALS.59-62 
Furthermore, about 2% of the male patients diagnosed with ALS actually have Kennedy 
disease (SBMA, X-linked spinobulbar muscular atrophy) caused by a trinucleotide 
expansion in the androgen receptor.63, 64 Autosomal dominant inheritance of FALS 
occurs in approximately 5- 10% of ALS patients and is clinically and neuropathologicaly 
indistinguishable from sporadic ALS.65 Dominant FALS is characterized by large intra- 
and interfamilial variability of age of onset and progression. Incomplete penetrance has 
been observed in pedigrees 66-69 and confirmed by mutation analysis.70 
Autosomal dominant FALS is genetically heterogeneous; currently two genes, one on 
chromosome 21 (SOD1 gene) and one on chromosome 17 (tau gene) and three additional 
loci (one on chromosome 18 and two on chromosome 9) are known (Table 1). 
Before linkage analysis and molecular diagnosis of ALS through molecular analysis 
became available, autosomal recessive FALS was considered very rare. However, currently 
already three forms of recessive ALS are recognized, and the genes for two of those, SOD1 
(ALS1) and alsin (ALS2) have been identified. Altogether the now established forms of 
FALS account for probably 20-30% of FALS.
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Table 1. Genetics of Amyotrophic Lateral Sclerosis (ALS)
Classification Gene Localization Inheritance Ref.
Major genes
ALS1 SOD1 21q22 AD/AR 73,75
ALS2 alsin 2q33-34 AR 126,127
ALS3 unkown AD
ALS4 9q34 AD 128
ALS5 15q12-21 AR 129
ALS6 18q21 AD 131
FTDP tau 17q21.2 AD 132, 138
FTD 9q21-22 AD 155
Susceptibility genes
Neurofilament heavy chain NF-H 22q12.2 187
Neurofilament light chain NF-L 8p21 191,193
Peripherin PRPH 12q12-13 182
Glutamate transporter EAAT2 11p13-12 215
Glutamate receptor AMPA 5p33 207
Apolipoprotein E ApoE 19q13.2 219
Ciliairy neurotrophic factor CNTF 11q12.2 230
Debrisoquine hydroxylase CYP2D 22qq13.1 233
Apurinic apyrimidinic endonuclease APEX 14q11-12 236
Mitochondrial DNA COX 246
Manganese superoxide dismutase SOD2 6q25 248
P2 Blood Group P2 22q11 262
 
AD, autosomal dominant; AR autosomal recessive; SOD, superoxide dismutase; FTD, 
frontotemporal dementia-ALS complex; FTDP, frontotemporal dementia and parkinsonism 
complex.
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ALS1 (SOD1) 
In 1991 the first ALS gene (ALS1) for an autosomal dominant form of FALS was mapped 
to chromosome 21q.71 Two years later the cytosolic copper-zinc superoxide dismutase 
(SOD1) gene was shown to be the ALS1 gene.72 SOD1 is a 153- amino acid metalloenzyme 
with high expression in nervous tissue, liver and erythrocytes. The enzyme catalyses the 
conversion of the superoxide radical anion (O
2 
-) to molecular oxygen (O
2 
) and hydrogen 
peroxide (H
2
O
2
). Presently, over 90 different mutations in all five exons of this gene have 
been identified.65 All these SOD1 mutations are associated with autosomal dominant FALS, 
except two, D90A and D96N that can cause both dominant and recessive ALS.73-76 
SOD1 mutations have been detected in 195/916 families showing autosomal dominant 
ALS, suggesting that SOD1 is implicated in ± 21% (range 13-84 %) of dominant FALS.65, 
72, 77-83 Additionally, 112 of 946 apparently sporadic ALS patients or about 12% (range 2.5-
23%) was heterozygous for a SOD1 mutation.65, 78, 84, 85 The mutation pattern in sporadic 
ALS is similar to FALS.86, 87 Sporadic ALS due to one SOD1 mutation may represent a new 
dominant mutation, or incomplete penetrance of a dominant mutation in the parents. Some 
of the SOD1 mutations occur as recurrent mutations or as founder mutations sometimes 
having a worldwide distribution. The A4V mutation, the most frequent SOD1 mutation 
overall, is yet only found in patients from North America.73, 86 
Most mutations in the SOD1 gene associated with FALS behave as dominant traits. 
However, the D90A mutation can also be recessively inheritated. This missense mutation 
involving an A to C transversion giving rise to substitution of aspartic acid by alanine at 
codon 90 can cause ALS both in the homozygous state or in the compound heterozygous 
state with the D96A mutation.76, 88 The recessive inheritance of the D90A mutation has 
been reported mainly in Scandinavian families.74, 80, 84 In other parts of the world the D90A 
mutation is a rare cause of recessive FALS and usually causes ALS in the heterozygous 
state.75, 82, 85, 86, 89, 90 In the Northern Scandinavian population homozygotes for this mutation 
show a uniform disease phenotype with insidious onset (mean age at onset: 44 years, 
range 20-94): the slowly ascending paresis begins distally in the lower extremities and has 
relatively slow progression (mean survival: 14 years).82, 84 In the population of northern 
Sweden and Finland this type of ALS1 is responsible for 9.6% (44/451) of ALS,80, 91 and a 
tenfold increase of the allele frequency of the D90A mutation in this population was found 
(1 to 2 %).84, 92 A study of 28 recessive D90A pedigrees showed that 20 families shared the 
same founder haplotype,93 whereas several founders were detected in 8 families with the 
dominant D90A mutation Therefore, it was suggested that there might be a protective factor 
that is tightly linked to the SOD1 mutation in the genetically rather homogenous northern 
Scandinavian population and reduces susceptibility to ALS, which would also explain the 
very long disease duration in the Scandinavian patients.
The majority of SOD1 mutations are missense mutations and there is no clear correlation 
36
CHAPTER 3
with the clinical expression of the disease (genotype-phenotype correlation).65, 80, 86 This 
inter- and intrafamilial variability precludes precise predictions on the course of the 
disease. Clinical characteristics age at onset and survival vary greatly between and among 
specific mutations. The phenotypic variability extends from rapidly progressive disease 
with only lower motor neuron signs to a very slowly progressing disease with upper and 
lower motor neuron signs.70, 94-96 Typically, in one family with dominant ALS with a D90A 
mutation of the SOD1 gene, manifestations ranged between juvenile focal amyotrophy 
of the arm to classical symptoms of ALS in another relative.75 Even non-penetrance was 
recently found for some SOD1 mutations, including the I113T, V4G, A76T, G21L, A101A 
and G16S mutations,69, 97, 98 although penetrance of most SOD1 mutations may seem high 
(80% at age 85 years) in families ascertained for familial ALS.66
Some of the SOD1 mutations often are associated with ‘early onset’ (G37R, L38V), ‘shorter 
survival’ (A4V) or relatively ‘benign’ forms of ALS (G37R, G41D, G93C, and H46R).70, 79, 
83, 86, 99-101 However, these associations must be interpreted with caution when used to give 
a prognosis in individual cases. Onset of disease with progressive bulbar paralysis seems 
quite rare in ALS1 patients (reported once in a case with a deletion of the SOD1 gene).102 
Sometimes extreme differences in survival within some families with ALS have important 
implications for genetic counseling in these families, and raises fundamental biological 
questions concerning the existence of modifying properties of additional genetic or 
environmental risk factors. 
It is unclear how SOD1 mutations cause ALS. As the level of residual SOD1 enzyme 
activity does not correlate with disease expression in ALS patients, the loss of function 
of SOD1 is not a likely cause of motor neuron degeneration.103 This is corroborated by the 
observation that knockout mice models have no ALS phenotype.104-106Actually, dominant 
SOD1 mutations are thought to act as gain-of-function mutations inducing mutant 
SOD1 proteins that are selectively toxic to motor neurons. The mutant proteins might be 
responsible for the intracellular aggregation of neurofilamentous protein in neurons and 
astrocyts, that coincides with disease onset and increases as disease progresses.107,108 
Studies of transgenic mice carrying mutated SOD1109 suggest that variation in expression 
of neurofilament influences selective vulnerability of motor neurons and slows down 
the toxicity of mutant SOD1 (see: neurofilament gene); other evidence suggest that 
abnormalities in the neurofilament organization may not be essential for SOD1- mediated 
ALS.110,111 
Other toxic effects of SOD1 mutations may involve increased vulnerability to excitotoxic 
mechanisms by selective inactivation of the glutamate transporter EAAT1,112-114 or by 
mitochondrial degeneration.115 Recent work on SOD1-transgenic mice has shown that 
mutant SOD1 proteins may exert their toxic properties by decreasing calcineurin activity 
(CaN; an enzyme regulating neuronal excitability by controlling the activity of ion 
channels and the release of neurotransmitter).116,117
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Neurofibrillary depositions and Lewy body-like inclusions belong to the pathological 
spectrum of ALS1.86,118 Neurofilamentous inclusions in motor neurons may occur 
in patients with the A4V and H48Q mutations. Also I113T mutation (which is the 
second most common SOD1 mutation) seems to predispose to extensive intraneuronal 
neurofilament depositions and multisystem distribution of intraneuronal neurofilament 
accumulation.95,102,118-121 Immunohistochemical co-localization of SOD1 in neuronal Lewy 
body-like hyaline inclusions (LBHIs) in the spinal cords of ALS1 patients indicates that 
SOD1 is a component of LBHI.122 Co-localization of copper chaperone (CCS) and SOD1 
suggests a specific interaction of SOD1 and CCS in the formation of LBHIs in ALS.123
ALS2 (ALSIN)
Autosomal recessive FALS was first described in a large inbred family in Tunisia showing 
linkage to the chromosomal region 2q33-34. Symptoms occur in the first or second decade 
of life, and include progressive spasticity of the limbs and the facial and pharyngeal 
muscles. Survival is relatively long (range from 15 to 20 years).124 
Recently, the gene for ALS2 was identified in Tunesian and Kuwaiti families and named 
alsin or ALS2.125-127 Alternative splicing of this gene produces a short and a long transcript. 
Deletions affecting both transcripts result in the ALS2 phenotype, whereas homozygous 
deletions in exon 9 and affecting only the short form of the protein cause juvenile primary 
lateral sclerosis (JPLS). JPLS is even more rare than ALS2, and its phenotypic presentation 
consists of slowly progressive spastic paraparesis and muscle weakness of the oro-facial 
and ocular muscles.
Expression of the mouse orthologe of alsin was found in neuronal cells throughout the 
brain and spinal cord. Because alsin has protein domains with similarities to pleckstrin 
and guanine-nucleotide exchange factors (GEFs) known to activate GTPases, alsin may 
act as a regulator/activator of GTPases, and modulate microtubuli assembly, membrane 
organization and trafficking in neurons. 
ALS3
The majority of dominant FALS has not yet been assigned to any given locus and was 
lumped into the designation ALS3.71 
ALS4
A second form of autosomal dominant FALS (ALS4) has been localized to a locus on 
chromosome 9q34 in an extended family with juvenile onset (mean age at onset 17 years) 
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and slow progression without bulbar involvement. However the ALS4 gene has not yet 
been identified. Patients initially show difficulty in walking, followed by weakness and 
wasting of muscles of the hand and distal lower extremities. Significant proximal weakness 
occurs in the 4th or 5th decade, with loss of useful hand function by the 6th decade. 
Neuropathological evaluation disclosed degeneration extending to the dorsal roots, dentate 
nucleus, nucleus gracilis, and inferior olivary nucleus.128
ALS5 
This form of autosomal recessive FALS is clinically similar to ALS2.129 ALS5 may be the 
most prevalent form of recessive ALS, and was identified in several ethnic groups (North-
African, South-Asian, and European). The ALS5 gene was mapped to chromosome 15q, 
but the gene remains to be identified.130
ALS6
Only recently, a third locus for autosomal dominant FALS was mapped to chromosome 
18q21 in a large European family with classic adult-onset ALS.131
Tauopathies 
ALS1, ALS4 and ALS6 represent pure forms of FALS. However, ALS can also be part of 
a multisystem neurodegeneration including the tauopathies and the combination of ALS 
with dementia and parkinsonism. Mutations in the tau gene are associated with a clinical 
phenotype that includes frontotemporal dementia, Pick’s disease, corticobasal degeneration, 
and familial progressive supranuclear palsy. This phenotype shows variability both within 
and between different families.132-137 The variability of clinical symptoms suggests that 
tau pathology may play a role in a large number of neurodegenerative diseases, including 
ALS, where neurofilamentous deposits mainly consisting of hyperphosphorylated tau 
protein occur. Tau mutations were first recognized in a syndrome consisting of frontal 
lobe dementia, parkinsonism and amyotrophy (FTDP).132, 138 FTDP is characterized by 
autosomal dominant inheritance of behavioral disturbances, reduced speech and memory 
impairment, whereas parkinsonism and amyotrophy may occur late in the course of the 
disease The prevalence of FTD is estimated to be 2.8 per 100.000 in the 60-70 year-olds.139 
The proportion of families with FTD having a mutation in the tau gene varies from 13% to 
approximately 40%.140-142
In FTDP the mutations of the tau gene affect the alternative splicing of exon 10 of 
the tau gene, resulting in an excess of four-repeat tau isoforms. The effect of four-
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repeat protein tau- isoforms on neurodegeneration could consist of a reduced binding 
of tau to microtubules in axons. That might explain the accumulation of tau protein as 
hyperphosphorylated neurofilaments in the cytoplasma, leading to central and peripheral 
axonopathy that results in neuronal death and amyotrophy.143-146 
Guadeloupean parkinsonism, associated with frontolimbic dementia and ALS is also 
considered a tauopathy because of the accumulation of tau proteins, predominantly in the 
midbrain. Although no mutations in the tau gene were observed in this group of patients, 
all cases were homozygous for the H1 tau haplotype. 147 The tau polymorphism CA3663 is 
associated with the ALS, dementia-parkinsonism complex of Guam, indicating that tau is 
not the cause of this disease but probably acts as a susceptibility gene.148, 149
ALS with dementia and parkinsonism 
The clinical phenotype of FALS can consist of pure ALS, multisystem degeneration in the 
tauopathies, and ALS in association with dementia and parkinsonism. Some mutations in 
SOD1 may cause ALS associated with dementia, as observed in a family with the A76T 
mutation.80 Parkinsonism is seen less often, suggesting reduced toxicity of SOD1 mutations 
to nigrostriatal dopaminergic neurons.150The Guamanian type ALS is characterized by the 
familial co-occurrence of dementia, parkinsonism and motor neuron signs. Analysis of 
the SOD1 gene in this disease found an I113T mutation in (2 of 23 unrelated) ALS patients 
from the Kii Peninsula of Japan.83, 98, 151, 152 
Also other genes predisposing to age-related multisystem neurodegeneration represent a 
genetic contribution to ALS. Mutations in the tau gene cause varying symptomatology 
as was recently demonstrated in the frontotemporal dementia and parkinsonism complex 
(FTDP)132, 137, 138, 153, 154 and in familial atypical progressive supranuclear palsy. 133 Whereas 
the ALS-frontotemporal dementia-complex (FTD) is linked to chromosome 9q (Table 1).155 
However, these genes do not account for all of the familial aggregation of ALS, dementia 
and parkinsonism.156, 157 
Epidemiologic studies have revealed familial aggregation of classic ALS, dementia and 
parkinsonism suggesting that common genetic factors may contribute to all three disorders. 
A significant increase in the risk for dementia as well as for parkinsonism in first- and 
second- degree relatives of ALS patients has been found in several case-control studies.12, 
158-160 The cumulative incidence of dementia to age 90 was significantly higher (15%) in 
relatives of ALS patients than in relatives of controls. Furthermore the lifetime risk for 
parkinsonism is 7% for relatives of ALS patients, a twofold increase compared to relatives 
of controls.158 Epidemiologic data also indicated an excess of familial co-occurrence of 
dementia and parkinsonism in families of patients with ALS: patients with sporadic ALS 
were 12 times more likely to have relatives with parkinsonism, if a relative had dementia 
than if there was no family history of dementia.161 This excess aggregation probably reflects 
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a genetic susceptibility to widespread neurodegeneration.
Apart from the 4 loci described above, many more genes are involved in syndromes 
with ALS, dementia and/or parkinsonism. Machado-Joseph disease shows familial 
amyotrophy associated with parkinsonism and spinocerebellar symptoms, and is caused by 
expansion of trinucleotide repeats in the SCA3 gene on chromosome 14. Other examples 
of genetic disorders presenting with both pyramidal and extra-pyramidal symptoms 
are familial aggregation of motor neuron disease, tic disorder and parkinsonism due to 
neuroacanthosis,162-164 and the autosomal dominant inherited entity of parkinsonism and 
amyotrophy.165-170 A familial ALS- dementia complex with autosomal recessive inheritance 
was reported in some families, including inbred Old Amish sib ships. The latter type of 
ALS presents with a juvenile form of ALS and an exceptional long survival (from 9 to 
27 years) and is variably accompanied by dementia.171, 172 Another familial ALS-dementia 
complex shows an autosomal dominant inheritance pattern.173-177 The familial occurrence of 
ALS with symptoms of dementia, parkinsonism, or other CNS symptoms is also observed 
in a growing number of other genetic multisystem neurodegenerative disorders including 
Huntington disease, or neuroaxonal dystrophy.178, 179 Therefore family histories of persons 
with ALS might be carefully analysed not only for ALS, but also for the often-related 
disorders of dementia and parkinsonism. . 
Susceptibility genes
Considering that mutations in ALS genes occur in familial as well as sporadic ALS 
patients, probably more than 10% of ALS can be explained by the multiple autosomal 
dominant and recessive forms. Since there is still no evidence for any specific 
environmental cause for sporadic or familial ALS, most remaining cases of the disease are 
thought to result from interaction of several genes and environmental factors.
We describe here some of the genes potentially contributing to the development of ALS. In 
this broader complex genetic context, these genes are referred to as ‘susceptibility genes’ 
as mutations in these genes may only lead to ALS in the presence of other genetic or 
environmental risk factors.
 
Neurofilaments  
Abnormal accumulation of intermediate filaments (IF) in the perikarya and proximal 
axons of motor neurons is a common pathological hallmark of ALS, suggesting that 
abnormalities in neurofilament organization may be involved in the pathogenesis of ALS.180 
Neurofilaments are the principal intermediate filament type expressed by motor neurons. 
They are formed by the co-assembly of three sub-units: NF-L (light subunit), NF-M 
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(medium subunit), and NF-H (heavy subunit). NF-L is necessary for filament assembly, 
whereas NF-M and NF-H form links with other neurofilaments in axons.181 Peripherin, 
another intermediate filament, is associated with axonal spheroids in the degenerating 
motor neurons of ALS patients.182 Transgenic mice overexpressing peripherin in motor 
neurons develop late onset motor neuron disease.183, 184
It is unclear whether the IF accumulations in ALS occur as a secondary feature of ALS-
associated neurodegeneration or represent the primary cause of disease.
Several lines of evidence suggest that neurofilament genes play a causal role. First, variant 
alleles of the neurofilament heavy-subunit gene (NF-H) have been found in ~1% of more 
than 1300 sporadic and in 0.3% of 295 familial ALS patients, but not in control DNA.185-190 
However in transgenic mice overexpression of wild type NF-H proteins leads to atrophy of 
motor neurons.3, 191, 192 Second, in situ hybridization studies revealed considerable reduction 
in NF-L mRNA levels in degenerating spinal motor neurons of ALS patients.193 A role of 
NF-L dysfunction in neurons is further suggested by the observation that NF-L deficiency 
accelerates motor neuron signs in mice overexpressing peripherin.183, 194 Also a NF-L 
mutation in a family with neuronal Marie-Charcot-Tooth (type 2) disease was detected. 195 
Furthermore, mice transgenic for a mutant NF-L gene develop severe perikaryal and axonal 
degeneration of motor neurons.191, 196 
The presence of abnormal neurofilament accumulations in FALS associated with 
SOD1 mutations,95, 118, 121 and in mice expressing mutant SOD1 endorses involvement of 
neurofilamentous pathology also in ALS1. Surprisingly, experiments with SOD1 transgenic 
mice, show that both the absence of NF-L neurofilaments (causing a depletion of axonal 
IF and a decrease in axonal conductivity)197 and overexpression of the NF-H gene (causing 
perikaryal increase of IF) can cause a decrease in vulnerability and increase in survival 
of the motor neurons.110, 111, 181, 198, 199 These studies also showed that perikaryal and axonal 
aggregates contain peripherin.200 
In conclusion, IF variants are likely modifying risk factors in sporadic ALS and probably 
modulate disease expression in SOD1- related ALS.201
Excitotoxicity genes 
The term excitotoxicity refers to a phenomenon in which the excessive or prolonged 
activation of excitatory amino acid receptors results in damage and eventually death 
of the involved neurons. The activation of these receptors leads to depolarization and 
neuronal excitation and is normally transitory. Excitatory damage of neuronal cells 
appears to be mediated by sustained elevations of intracellular calcium levels. In line with 
this, high levels of the calcium-binding protein paralbumin were found to delay motor 
neuron degeneration in double transgenic SOD1/ overexpressing paralbumin mice.202-204 
That excitotoxic mechanisms are implicated in the pathogenesis of ALS is further based 
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upon several observations. Levels of glutamate, the major excitatory transmitter in the 
motor neuron system, are increased in the cerebrospinal fluid of ALS patients,205 whereas 
glutamate transport is reduced in the brain and spinal cord of ALS patients.206 Motor 
neurons are vulnerable to excitotoxicity mediated by the glutamate receptor α-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA),114,207,208 and ingestion of excitotoxins 
may contribute to the pathogenesis of the ALS-parkinson-dementia complex of Guam.209,210 
Riluzole, an antiglutamate drug, is yet the sole drug shown to provide some therapeutical 
effect in ALS.
Depolarization of the neuronal membranes after activation of neuronal glutamate receptors 
activates voltage-dependent calcium channels, allowing calcium to entry the cell. The 
excess activation of neuronal glutamate receptors causing cell death via increased cellular 
calcium may be one mechanism involved in motor neuron disease. Glutamate can also 
produce neuronal degeneration by increasing tau mRNA expression and phosphorylated 
tau protein, as observed in neuronal cultures.211-214 Decrease of glutamate transport may 
provoke elevated synaptic glutamate concentration. One of the four glutamate transporter 
proteins, the EAAT2 isoform, is involved in keeping extracellular glutamate levels below 
excitotoxic levels in the nervous system. 
In 60% of sporadic ALS, a 30%-95% loss of EAAT2 activity is observed in the motor 
cortex and spinal cord but not in other brain regions.204, 215, 216 The presence of variant 
mRNA transcripts of EAAT2 in these ALS cases could not be explained by mutations in 
the EAAT2 gene 216-218, and other mechanisms must therefore be responsible for these low 
levels of EAAT2. Since SOD1 gene mutations were found to inactivate EAAT2, SOD1 
mutations may partially, explain the decreased levels of EEAT2 in ALS.112, 113
Apolipoprotein E
The frequencies of apolipoprotein E (ApoE) ε2, ε3 and ε4 genotypes in familial and 
sporadic ALS are not different from those in the general population,219 thereby excluding 
ApoE mutations as a primary cause of ALS. However, the ApoE genotype was reported 
in some studies to have an effect on the age of onset and clinical presentation of sporadic 
ALS. The ε3/ε3 genotype may prolong survival in ALS patients, whereas the ε4 allele may 
predict an earlier age at onset.220 A significantly higher proportion of ALS patients with the 
ε3/ε4 genotype had bulbar symptoms, while the ε2/ε3 genotype seemed to predispose to 
limb onset of the disease. Therefore, as in Alzheimer disease, a protective role in ALS of ε2 
and ε3 alleles, and a deleterious role of the ε4 allele have been suggested.221-223 
The exact mechanism of the deleterious effect of the ε4 allele is unknown, but it may 
simply result from the absence of the protective alleles ε2 and ε3. The ε2 and ε3 gene 
products of ApoE have cysteine residues that are important in the detoxification of a 
lipid peroxidation product, 4-hydroxynonenal (HNE), which causes apoptosis and which 
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is increased in the spinal cord of ALS patients. The ε4 gene product has no cysteine 
residues, and therefore lacks the ability to protect against HNE-mediated apoptosis. 
This might explain the relationship between these ApoE genotypes and susceptibility to 
neurodegeneration.224 However, other studies do not confirm the association of the ε4 
allele with early onset, shortened survival or the presence of bulbar symptoms at onset in 
ALS.219, 225, 226 Also in patients with the ALS -parkinsonism-dementia complex of Guam no 
association was found with any of the ApoE alleles.29, 227
Ciliary neurotrophic factor (CNTF)
Diminished levels of ciliary neurotrophic factor (CNTF), a survival factor in spinal 
motor neurons, might contribute to the development of ALS. This is based upon several 
arguments. First, a decrease in CNTF levels was found in the corticospinal tract neurons 
of ALS patients.228 Second, abolition of CNTF gene expression in knockout mice causes 
progressive motor neuron degeneration.229 Third, the frequency of the homozygous state for 
a mutation in the CNTF gene leading to absent CNTF is slightly increased in sporadic ALS 
patients.230 As heterozygosity for CNTF mutations, is not increased in ALS patients, the 
role of CNTF in ALS seems modest.230, 231 
Cytochrome P450 debrisoquine hydroxylase (CYP2D6)
Protein polymorphisms in the cytochrome P450 debrisoquine hydroxylase gene (CYP2D6) 
are responsible for diminished metabolism of exogenous toxins, hereby forming one of the 
risk factors for Parkinson disease.232 Three studies have addressed the role of the CYP2D6 
(b) allele as a risk factor for ALS. One study found no association between this allele 
and ALS among 57 ALS patients and controls.233 The second study found a significant 
increase in the frequency of the CYP2D6(b) allele in 50 ALS patients.234 In the Chamorro 
individuals the frequency of this mutant allele was higher than in Caucasians, but no 
differences were found between healthy Chamorro people and patients with Guamanian 
ALS- dementia-parkinsonism complex.29
 
Apurinic apyrimidimic endonuclease (APEX) 
The DNA repair enzyme apurinic/apyrimidinic endonuclease (APEX nuclease) might 
be a risk factor for ALS as reduced levels of APEX nuclease were found in the frontal 
cortex of ALS patients.235 There are two reports of APEX gene mutations resulting in a 
decreased level and activity of the enzyme in ALS: mutations were found in 4/117 patients 
with sporadic ALS and in 4/9 twins with ALS, but not in controls.236-238 Apex nuclease 
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may also play a role in the Guamanian ALS-dementia-parkisnonism complex, since a 
metabolite of cycasin, methylazoxymethanol (MAM), a potential environmental genotoxin 
in Guamanian ALS, was found to cause significantly reduced neuronal APEX levels and 
activity.48 Although APEX mutations do not seem to account for a large proportion of ALS, 
the role of DNA damage in the etiology of ALS may be important. 
Mitochondrial metabolism 
Evidence that either inherited or acquired mitochondrial dysfunction plays a role in the 
pathogenesis of ALS is accumulating.239 Mitochondrial dysfunction has been detected 
in muscle biopsies of sporadic ALS patients,240 and increased oxidative damage has 
been found in the central nervous system tissue from autopsied familial and sporadic 
ALS patients.241-243 Mitochondrial vacuolisation is an early pathological feature in 
SOD1-mutated transgenic mice, suggesting that the leakage or translocation of mutant 
SOD1 in mitochondria may be the primary event triggering further degeneration.105, 
115, 244, 245 Additionally, mutations in mt DNA, including multiple mtDNA deletions or 
depletion of mtDNA,246 and a mutation of the mitochondrial DNA-encoded subunit 1 of 
cytochrome-c oxidase have been reported in ALS.247 Mitochondrial dysfunction in ALS 
may also be due to decreased levels of mitochondrial manganese superoxide dismutase 
(SOD2). This mitochondrial enzyme is encoded for by a nuclear gene on chromosome 
6. An Ala9Val mutation in SOD2 has been found in some patients with sporadic ALS,248 
whereas degeneration of neurons in basal ganglia and brainstem, and progressive motor 
disturbances with paresis occur in SOD2 knockout mice.249, 250 Furthermore, cultured 
murine cortical neurons with reduced levels of SOD2 are more sensitive to glutamate 
neurotoxity than neurons with intact SOD2 activity.251 Dysfunction of SOD2 exacerbates 
disease expression in SOD1 transgenic mice.252 
Additional candidate genes
Various additional ‘candidate genes’ for ALS as a monogenic entity or a multifactorial 
disease have been proposed. Despite the fact that SOD1 is involved in ALS through 
mechanisms probably not related to antioxidant activity, candidate genes for familial ALS 
include genes involved in free radical removal. A cytosolic protein termed the copper 
chaperone for superoxide dismutase (CCS) mediates the delivery of copper to SOD1. 
Experiments with CCS knockout mice show a marked reduction in SOD1 activity,251 
suggesting that CCS might play a role in ALS.253 
The association of the B allele of monoamine oxidase (MAO-B), a generator of free 
radicals, with a later age-at-onset of ALS suggests a role for oxidative damage in ALS.254 
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The Bcl-2 gene, encoding a protein that inhibits apoptosis, might be involved in ALS, as 
it attenuates neurodegeneration in SOD1-mediated ALS models.255 The spinal cords of 
patients with sporadic ALS may display increased expression of the transcription factor
c-jun mRNA, suggesting that c-jun is involved in the neurodegenerative processes of 
ALS.256, 257 
Another set of candidate genes is derived from the association of ALS and lymphoma.258-
261 A region on the long arm of chromosome 22 near the neurofilament gene may contain 
several genes that may modulate susceptibility to ALS: the blood group phenotype P2 
is overrepresented in ALS patients (43% of U.S. veterans with ALS, more than twice 
as frequent as expected),262 and appears extremely frequent (66%) in the indigenous 
Chamorros of the islands Guam and Saipan.263 The P2 blood group is equally frequent in 
the population in the northern part of Sweden, where the recessively inherited D90A SOD1 
mutation prevails.93, 264 Close structural similarity of P2 to GM
1
 ganglioside may explain 
the characteristic immunologic features of ALS patients, such as the increase in IgM 
antibodies against GM
1
 ganglioside by cross-reactivity against the P-system blood group 
antigens.265 Other genes that might involve predisposition to ALS are the interleukin-2 
receptor beta chain gene, localized to 22q11.2-q12, which is a locus for many neodysplasias 
of the lymphoid system, and the leukemia inhibitory factor gene (LIF) on 22q12.1-
q12.2.266 Recently, knockout mice for the hypoxia-response element (HRE) of the vascular 
endothelial growth factor (VEGF) gene were shown to develop an ALS-like condition, but 
VEGF mutations have not yet been identified in human ALS.267
ALS: a multifactorial disease
In view of the abundance of genetic and environmental factors that contribute to the 
pathogenesis of ALS, this disease is a paradigm for multifactorial diseases. These are also 
referred to as “complex diseases” because of the complex interaction between genetic and/
or environmental factors.
Gene- gene interaction
There are strong indications of gene-gene interaction and/or interaction of gene products. 
The selective detrimental effect of mutated ALS genes suggests an interaction with genes 
that are specifically expressed in neurons. Alternatively a neuron-specific lack of protection 
against the detrimental effect of ALS genes may exist. 
Recently, experiments with double transgenic mice demonstrated mutual effect-
modification of ALS genes (SOD1, neurofilament, excititoxicity and mitochondrial 
genes). The genetic effect-modification may result from a novel interaction of altered 
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gene-products (protein-protein interaction). Alternatively, it is conceivable that abnormal 
proteins modulate gene expression (protein-gene interaction).268 
Experiments with transgenic mice have effectively demonstrated that mutations in the 
neurofilament gene slow down SOD1- mediated ALS. The interactive effect of genes may 
also enhance neurodegeneration, like the increase in excitotoxic vulnerability observed 
in SOD1 mutations, tau gene upregulation by glutamate toxicity,212 and the coincidence of 
a high prevalence of the rare P2 blood group in the native inhabitants of Guam and in the 
Scandinavian population, where SOD1 mutations cause a rare recessive form of ALS1. 
Gene- environment interaction
Gene-environment interaction is suspected when a specific environmental risk factor 
modulates the risk for disease in persons with a susceptibility genotype. Exogenous 
control of gene expression should be considered as a possible cause of neurodegeneration 
for instance in the Guamanian ALS. The observation that intraneuronal neurofilamentous 
aggregations (a neuropathological hallmark for guamanian ALS/ PDC) are frequent 
in the indigenous Gamorro population of Guam, where consumption of cycad nuts is 
high, may lead to the hypothesis that for the specific subgroup of this population with a 
genetic predisposition to neurofilamentous accumulation, ingestion of cycad nuts may 
be more harmful.269, 270 The prevalence of a specific polymorphism in the tau gene in the 
Guamaninan population, distinct from the splice site mutations in FTDP-17,149 and the 
observation that cycasin may cause persistent upregulation of tau mRNA expression,48 
suggests that tau polymorphisms may increase susceptibility to cycasin-modulated tau 
expression. Also specific polymorphisms of the CYP2D6 gene, occurring more frequently 
in the Chamorro population may increase susceptibility to locally prevalent environmental 
toxins.29
Detection of environmental risk factors involved in gene-environment interaction in 
ALS is difficult because ALS is genetically heterogeneous and a specific exposure may 
convey only a small increase in risk. Furthermore the pathogenic mechanism of mutated 
ALS genes may vary per gene or even per mutation, some acting through neurofilament 
accumulation others by an excitotoxic pathway. Each of the ALS genes or each mutation in 
those genes may respond to a different environmental trigger. Probably, the most feasible 
approach to study gene-environment interaction in ALS is to evaluate the additional 
effect of environmental factors on specific mutations in ALS genes (because variable 
expression in monogenic ALS may depend on exogenous exposure) or on allelic variance 
of susceptibility genes, as was previously done for Alzheimer’s dementia.271 Identification 
of gene-environment interaction is of great importance because identification of exogenous 
influences on the course of the disease will help to find ways to prevent disease in at risk 
individuals. Furthermore, it might shed light on the pathogenesis of ALS.
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 ALS: an unifying hypothesis?
Neuropathologically, the different types of familial and sporadic ALS are characterized 
by similar neurofilamentous neuronal inclusions. These findings suggest a common 
pathogenesis of motor neuron degeneration in all types of ALS. The major challenge 
of current research is to find out the role of mutations in the major ALS genes and of 
‘susceptibility’ genes, in terms of pathogenic mechanism. 
Many of the neurodegenerative diseases, including ALS, Alzheimer’s dementia, 
Pick disease, Parkinson disease, prion diseases and trinucleotide repeat diseases are 
characterized by senile plaques, Lewy bodies, neurofibrillary tangles, glial cytoplasmatic 
inclusions, spheroids, etc. All these lesions consist of proteins such as β- amyloid, tau, 
neurofilament, α synuclein, prions or expanded polyglutamine-containing proteins. It 
is, therefore, possible that all these neurodegenerative diseases result from an abnormal 
interaction between proteins, that not only leads to a loss-of-function of those proteins, but 
more importantly to a gain-of-function e.g. toxic effect on neurons eventually resulting 
in neuronal death.272 Novel therapeutic approaches aiming to prevent or reverse abnormal 
protein-protein interactions may show beneficial in the group of neurodegenerative 
disorders characterized by abnormal aggregation of proteins. 
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CHAPTER 4
A shared genetic susceptibility for 
amyotrophic lateral sclerosis, dementia, 
and Parkinson’s disease
Charcot faisant sa  leçon. 
Dessin à l’encre de Paul Richter. Extrait d’un cahier de note illustré 
pendant les leçons de Charcot à la Salpêtriè.
Provenance: La leçon de Charcot, voyage dans une toile. Exposition 
organisée au Musée de l’Asistance Publique de Paris 1986
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Abstract
Clinicians have long suspected an association of classical amyotrophic lateral sclerosis 
(ALS) with Parkinson’s disease (PD), dementia, or both. If proven, this would raise the 
possibility of a shared genetic susceptibility to the three disorders. To investigate this 
hypothesis, we compared 151 newly-diagnosed ALS patients (7 familial) with 140 controls, 
in terms of cumulative incidence of ALS, PD, and dementia in parents, siblings, and 
grandparents. We used Cox proportional hazards analysis to compute rate ratios (RRs) 
for ALS, dementia, and PD in relatives of ALS patients versus relatives of controls. The 
risk for dementia was significantly higher in relatives of ALS patients than in those of 
controls (RR=1.9, 95% CI 1.1-3.1), and was similar for relatives of patients with sporadic 
and familial ALS. The risk of PD was higher in relatives of patients with familial ALS 
(RR=5.6, 95% CI 0.6-50.3) than in relatives of patients with sporadic ALS (RR=1.8, 
95% CI 0.5-6.0), but these differences were not statistically significant, probably due 
to insufficient statistical power with the available sample size. These findings indicate 
that ALS and dementia, and perhaps also PD, co-occur within families more often than 
expected by chance, suggesting there may be a shared genetic susceptibility to these 
disorders.
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Introduction 
Amyotrophic lateral sclerosis (ALS) is a progressive, incurable neurodegenerative disorder. 
Clinically, ALS is distinguished from two other forms of motor neuron disease, progressive 
spinal muscular atrophy and progressive bulbar palsy, by the presence of both upper and 
lower motor neuron signs. In some areas of the Pacific (Guam, the Kii Peninsula of Japan, 
and Western New Guinea), ALS occurs endemically; there, ALS has been associated 
with a parkinsonism-dementia complex. 1 In the United States and Europe, ALS is rare 
(incidence 2 to 7 per 100,000 per year). 2
The pathogenesis of ALS is unclear. Like Alzheimer’s disease (AD) 3-5 and Parkinson’s 
disease (PD) 6, 7 ALS appears to be a complex disorder, in which the clinical manifestations 
used for diagnosis may be caused by more than one genetic defect, or may have other, 
nongenetic causes. Further, within some of the genetic forms, unidentified environmental 
exposures could be required for expression of the disease.
In 5 to 10% of cases, there is a family history of ALS, usually in a pattern consistent with 
autosomal dominant inheritance. In some, but not all, families with autosomal dominant 
ALS, there is close linkage with markers on the long arm of chromosome 21,8 and 
associations have been found with several different defects in the superoxide dismutase 
(SOD1) gene on chromosome 21. 9
ALS may be associated with clinical or pathological signs of AD or PD. All three are 
idiopathic degenerative diseases of aging, and all are characterized by the selective 
disappearance of specific sets of nerve cells followed by gliosis; hence, some have proposed 
a common etiopathology for the three disorders. 10-13 Some ALS patients also have signs 
of dementia, 14-24 parkinsonism, 25, 26 or both. 27, 28 In pedigrees with apparent autosomal 
dominant inheritance of ALS, dementia and ALS have co-occurred in the same individual 
29, 30, or in different individuals in the family. 31-33 Similarly, there may be co-occurrence of 
ALS and parkinsonism, 34, 35 or of all three disorders. 36, 37 
We used epidemiologic methods to investigate the hypothesis of shared genetic 
susceptibility to ALS, PD, and dementia. We assessed familial aggregation of these three 
disorders by comparing ALS patients and controls in terms of cumulative incidence of 
ALS, dementia, and PD in their relatives. 
Methods
We ascertained all clinically non-demented patients who were newly-diagnosed with ALS 
in 1989 to 1991 at the Neurological Institute, Columbia-Presbyterian Medical Center. 
We did not perform systematic neuropsychological testing on these patients, but none 
had symptoms of functional impairment suggestive of dementia. All ALS patients had 
electromyography (EMG) and were diagnosed by L.P.R. The clinical diagnosis of ALS 
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was restricted to patients with both upper (Babinski sign or clonus) and lower (weakness, 
wasting, fasciculation) motor neuron signs. We excluded patients with primary lateral 
sclerosis (N=5). 38
For each ALS patient, we selected another patient admitted to the Department of Neurology 
for stroke or scheduled for EMG on the nearest day who matched the ALS case by age 
(±5 years), gender, and payment status (Medicaid or Medicare vesus private) to serve as 
a control. If the first selected control refused or was unable to participate, we selected the 
next patient who matched the case. This procedure was repeated until a suitable control 
was found. We excluded candidate control subjects if their discharge diagnoses indicated 
any kind of dementia, PD, hereditary neuropathy, spinal muscular atrophy, or motor neuron 
disease. The diagnoses of the controls included stroke (23%), radiculopathy or spinal cord 
compression (36%), peripheral (sensory or motor) neuropathy (23%), multiple sclerosis 
(4%), and myopathy (9%). In the remaining 5%, no neurological abnormality was detected.
To prevent bias in participation, we invited each subject to participate in a study of “the 
causes of neurological disorders”, without emphasizing genetic factors. Subsequently, 
we administered a semistructured interview that asked for demographic and medical 
information on the patient and his/her siblings, parents and grandparents. Offspring were 
excluded from the study because we assumed they would be younger than the age periods 
at greatest risk for AD, PD, and ALS. D.M.-K. administered half of the interviews in 
person during the hospital admission or outpatient consultation, and half were administered 
by another interviewer by telephone within three weeks after discharge or outpatient 
consultation. There was no difference between the ALS patients and controls in terms of 
the proportion interviewed in person (ALS patients, 50%; controls, 40%). The interview 
included, for each relative, specific questions about diagnosed ALS, AD or any other kind 
of dementia, and PD and, independently of whether the relative was reported to be affected, 
additional information about decline in memory and functional ability, signs of PD 
(extrapyramidal signs including resting tremor, bradykinesia, postural instability, rigidity), 
and use of L-dopa or similar medication. 
The following questions were used to ascertain decline of memory and function in each 
relative: 
Did [relative] have any of the following problems for some time but not all of his/her 
life: (1)...trouble remembering things like a short shopping list, or things to do, or events 
that happened recently? (2)...trouble finding his/her way even in a familiar surrounding? 
(3)...needing help to dress or eat, not due to obvious physical disability? (4)...trouble 
remembering the exact date and/or year?
We classified relatives as affected with dementia if they were reported to have had AD or 
dementia, or had ≥ 2 affirmative answers to the four questions above. We did not attempt 
to differentiate among different types of dementia, because most affected relatives had 
died long before the introduction of clinical and pathologic criteria for subclassification 
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of dementia. 39 Eighty-two percent of relatives reported to have had AD also had ≥ 2 
affirmative answers to the questions above. We classified relatives as affected with PD if 
they were reported to have had PD. 
We also collected further data on other conditions in relatives, especially on syndromes 
presenting with dementia or parkinsonism (intracranial neoplasm, stroke, meningitis, 
alcoholism, multiple sclerosis, poliomyelitis, and arthritis). We classified relatives as 
unaffected if they were reported to have had a preexisting condition that might have led to 
dementia or parkinsonism. 
We requested medical records and autopsy reports for 53 relatives reported to have had 
PD, dementia, or ≥ 2 signs of dementia. For the remaining relatives reported to have been 
affected with PD or dementia, data were insufficient to locate the medical record. Forty-
three (81%) of the records requested were received, but only 23 of these (53%) contained 
useful information. (The remaining records contained information only on unrelated 
conditions.) All of the records with useful information confirmed the reported diagnoses. 
We did not request records for relatives reported to have had ALS because these family 
histories had already been well documented for the clinical records. 
We used survival analysis methods to control for differences in the years-at-risk of each 
disorder between relatives of ALS patients and relatives of controls. This method is 
appropriate for genetic studies of disorders of late onset, where some family members 
are too young to express the disease and some have died of other causes before the age at 
risk. 40 We assumed that each relative was at risk of ALS, PD, or dementia from birth until 
current age (if alive and unaffected), age at death (if deceased and unaffected), or age at 
onset of symptoms. Then we used actuarial life table analysis 41 to calculate cumulative 
incidence of each disorder by age in relatives of ALS patients and relatives of controls, 
where cumulative incidence estimates the probability that a relative would be affected by 
the time he or she reached a specific age. We used Cox proportional hazards analysis 42 
to calculate rate ratios (RRs) for each of the three disorders in relatives of ALS patients 
vs. relatives of controls. These RRs estimate the ratio of risk in relatives of ALS patients 
versus relatives of controls, assuming this ratio is constant with age. ALS patients who 
reported having one or more relatives (parent, sibling or grandparent) with ALS were 
classified as “familial ALS”. Analyses of risk of each disorder were then stratified by 
relationship to the patient or control (sibling, parent, or grandparent), and by familial versus 
sporadic ALS. 
Results
The participation rate was 96% for ALS patients and 89% for controls. The study 
population comprised 1,156 relatives (390 siblings, 302 parents, and 464 grandparents) 
of 151 ALS patients and 1,102 relatives (336 siblings, 280 parents, and 486 grandparents) 
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of 140 controls. Relatives with missing information on dementia were excluded from 
analyses of dementia (relatives of ALS patients: 5% of siblings, 9% of parents, and 
68% of grandparents; relatives of controls: 2% of siblings, 7% of parents, and 59% of 
grandparents), and those with missing information on PD were excluded from the analyses 
of PD (relatives of ALS patients: 5% of siblings, 11% of parents, and 68% of grandparents; 
relatives of controls: 2% of siblings, 7% of parents, and 60% of grandparents). Analyses 
of dementia included the remaining 793 relatives of ALS patients and 790 relatives of 
controls, while analyses of PD included 787 relatives of ALS patients and 782 relatives of 
controls.
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Figure. Cumulative incidence of reported dementia and PD in relatives (parents, siblings, and grandparents) of 
ALS patients and controls by age of relatives. Solid line, squares = dementia in relatives of ALS patients; dashed 
line, diamonds = dementia in relatives of controls; solid line, triangles = PD in relatives of ALS patients; 
dashed line, stars = PD in relatives of controls.
 
A family history of ALS was reported in 7 (4.6%) of the ALS patients and in none of the 
controls. Age at onset was similar in patients with familial ALS (mean ± SD:60 ± 17; range, 
45 to 79 years) and sporadic ALS (mean ± SD: 62 ± 14; range, 23 to 88 years). For all cases, 
the male:female ratio was 3:2. In ALS patients with onset ≤ 50 years, there were equal 
numbers of men and women; in those with onset > 50 years, there were more men (male:
female ratio, 2:1).
Dementia was reported twice as often in relatives of ALS patients (38/793) as in relatives 
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of controls (22/790). The cumulative incidence of dementia was significantly higher in 
relatives of ALS patients (risk to age 90: 15.4%, SE 2.9%) than in relatives of controls (risk 
to age 90: 7.5%, SE 2.1%) (figure) Among relatives of ALS patients, the risk of dementia to 
age 90 was 21.7% (SE 4.6%) in parents, 0.4% (SE 0.4%) in siblings, and 12.6% (SE 4.5%) 
in grandparents. Among relatives of controls, the risk of dementia to age 90 was 9.8% (SE 
3.1%) in parents, 0.5% (SE 0.5%) in siblings, and 7.4% (SE 3.4%) in grandparents. The RR 
for dementia in relatives of cases compared with relatives of controls was 1.9 (95% CI 1.1-
3.1), and was similar in relatives of familial and sporadic cases (table 1).
Table 1. Cumulative incidence to age 90 and rate ratio (RR) for dementia in 
relatives (parents, siblings, grandparents) of sporadic and familial ALS patients 
and controls
No.
of patients
or controls
No. of relatives
 Total*     with dementia
Cumulative
Incidence % 
(SE)
RR
(95% CI)
ALS patients
Familial   7  37  2 10.5 (7.0) 1.6 (0.4-7.0)
Sporadic 144 756 36 15.7 (2.1) 1.9 (1.1-3.2)
Total 151 793 38 15.4 (2.9) 1.9 (1.1-3.1)
Controls 140 790 22 7.5 (2.1) 1.0 (reference)
*Relatives with missing information on dementia were excluded from the analyses
 
Table 2. Cumulative incidence to age 90 and rate ratio (RR) for Parkinson’s disease 
in relatives (parents, siblings, grandparents) of sporadic and familial ALS patients 
and controls
No.
of patients
or controls
No. of relatives
                          with
 Total*     Parkinson’s disease
Cumulative
Incidence % 
(SE)
     RR
   (95% CI)
ALS patients
Familial   7  37 1 3.9 (3.7) 5.6 (0.6-50.3)
Sporadic 144 750 7 2.7 (1.2) 1.8 (0.5-6.0)
Total 151 787 8 2.7 (1.2) 1.9 (0.6-6.4)
Controls 140 782 4 1.7 (1.0) 1.0 (reference)
*Relatives with missing information on PD were excluded from the analyses
The risk of PD was twice as high in relatives of ALS patients as in relatives of controls, but 
this difference was not statistically significant (figure and table 2). Among relatives of ALS 
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patients, the cumulative incidence of PD to age 90 was 3.0% (SE 1.4%) in parents, 1.7% 
(SE 1.7%) in siblings, and 3.1% (SE 2.4%) in grandparents. Among relatives of controls, 
the risk of PD to age 90 was 3.5% (SE 2.3%) in parents, zero in siblings, and 0.6% (SE 
0.6%) in grandparents. The risk of PD was increased 5.6-fold in relatives of familial ALS 
patients, and 1.8-fold in relatives of sporadic ALS patients, but neither RR was statistically 
significant (table 2). The risk of PD was three times as high in relatives of familial versus 
sporadic ALS cases, but this difference was not statistically significant either (RR=3.1; 
95% CI 0.4-24.9). 
 
Discussion
Our finding of a two-fold increase in the risk of dementia in relatives of ALS patients 
compared with relatives of controls (table 1) implies that ALS and dementia co-occur 
in families more often than expected by chance. This familial aggregation of ALS and 
dementia is consistent with a previous report of an increased risk of ALS in relatives 
of dementia patients. 43 The 1.9-fold increased risk of PD in relatives of ALS patients 
compared with relatives of controls was not statistically significant. However, we cannot 
rule out a modest familial association of ALS and PD, because statistical power to detect 
the association with PD was insufficient with our available sample size.
Although previous reports have described patients and families with coexisting ALS, 
dementia, or PD, two previous epidemiologic studies failed to demonstrate significantly 
increased risk of neurodegenerative diseases in relatives of ALS patients. 44, 45 The findings 
of these two studies are difficult to interpret because of lack of specificity in the diseases 
examined in the relatives. The first study 44 compared ALS patients and controls in 
terms of their family histories in first-degree relatives of a diverse group of neurological 
disorders, and found an odds ratio of 2.2 that was not statistically significant. The second 
study 45 found no significant difference between ALS patients (12%) and controls (8%) 
in terms of the proportion of their first- and second-degree relatives over age 60 (parents, 
siblings, grandparents, aunts and uncles) affected with neurodegenerative diseases. It is 
unclear whether or not an association would have been observed if dementia and PD had 
been examined separately, and if the analysis had been restricted to first-degree relatives, 
in whom a shared genetic susceptibility would be expected to have the greatest effect 
(provided they are old enough to express late onset neurogenerative disorders).
Three aspects of our study design were intended to reduce bias. First, we avoided selection 
bias by describing our study objectives very generally when inviting subjects to participate, 
without mentioning genetic hypotheses. This should have eliminated the possibility of 
selective participation of ALS patients with a positive family history. Second, we attempted 
to reduce “family information bias” (ie, more complete recall of the family history by ALS 
patients than controls) 46 by choosing as controls patients who were hospitalized because 
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of severe neurological conditions, in whom the severity of their disorders might have 
evoked a level of concern comparable to that of the cases about the possible causes of their 
neurological problems. This should have minimized differences between cases and controls 
in recall of the family history, especially of neurological disorders. Third, to reduce 
reporting bias further, we used a very structured approach to obtaining the family history. 
Our family history questionnaire consisted of 30 questions on the family composition and 
an additional 17 questions for each relative separately. Except for two subquestions, these 
questionnaires were completely structured.  
We also evaluated the possibility of differential recall of the family history, by comparing 
ALS patients and controls in terms of the proportion of their relatives reported to have 
conditions that were unlikely to be associated with ALS. We found no difference between 
relatives of ALS patients and relatives of controls in the prevalence of a history of cancer 
(13% versus 14%), multiple sclerosis (0.4% versus 0.5%), poliomyelitis (0.4% versus 0.4%), 
or stroke (6% versus 7%), suggesting that recall bias is unlikely to account for our findings. 
We included grandparents in our study in order to increase the number of relatives 
who were old enough to be at risk of neurodegenerative disorders. (We excluded other 
second-degree relatives [aunts and uncles] because we found that few patients or controls 
were able to provide information about them.) For both ALS patients and controls, the 
validity of the family history data is expected to be inversely associated with distance in 
relationship, generally resulting in more underreporting in second-degree than in first-
degree relatives. 47 Since approximately 20% of the relatives included in the analysis were 
grandparents, underreporting is likely. Underreporting may be a bigger problem for PD 
than for dementia, because there is probably less general awareness of parkinsonism; 
some extrapyramidal signs may go unnoticed. 48 This would be expected to be especially 
problematic in grandparents, who would have been diagnosed with PD between 1910 and 
1930, when awareness of PD was even probably even lower than it is now. Underreporting 
may have lowered our estimates of cumulative incidence of dementia in relatives of ALS 
patients and controls and, if nondifferential between ALS patients and controls, may have 
biased our estimates of RR toward unity.
In addition, the effect of a shared genetic susceptibility is expected to be greater in first-
degree relatives (such as parents and siblings), who share 50% of the proband’s genes 
on average, than in second-degree relatives (such as grandparents), who share 25% of 
the proband’s genes on average. The risk of dementia (cumulative incidence to age 90) 
was nearly twice as high in the parents of ALS patients as in their grandparents (21.7% 
versus 12.6%), whereas in controls the difference in risk of dementia between parents 
and grandparents was smaller (9.8% versus 7.4%). These results are compatible with the 
hypothesis of a shared genetic susceptibility to ALS and dementia. 
We found very low risks of both dementia and PD in the siblings of ALS patients and 
controls. The average age of the siblings was only 60 years; thus, many very too young to 
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be affected by dementia or PD. These results are similar to those in the study of van Duijn 
et al., 49 where cumulative incidence of siblings of controls was 0.5% at age 65 (personal 
communication). 
ALS is likely to be etiologically heterogeneous; the shared genetic susceptibility to ALS, 
dementia, and PD probably applies to only a subset of the families of patients with either 
familial or sporadic ALS. The modest RRs for dementia and PD that we observed may 
mask a greater increase in risk in this subset of families. As noted by Weiss et al., 50 the 
existence of nongenetic phenocopies (ie, clinical symptoms expressed in persons without 
the high risk genotype) and reduced penetrance (ie, clinical symptoms not expressed, or 
expressed to a lesser degree, in some persons with the high risk genotype) can lead to small 
relative risks in family studies even when genetic factors are important. These problems 
may be especially important for PD, where most cases are believed to be nongenetic. 51 
Further, there is evidence for genetic heterogeneity in both AD 3-5 and PD. 6, 7
There are several alternative explanations for disease familial aggregation: culturally 
inherited risk factors, common environmental exposures, and shared susceptibility genes. 
Khoury et al. 52 showed that the effect of a familial environmental exposure on disease 
risk would have to be very strong to produce familial aggregation of the disease, and no 
environmental exposures with such strong effects have been identified for the diseases 
we studied. Further, most of the ALS patients and controls in our study were either 
immigrants to the United States or offspring of immigrants; their lifestyles and histories 
of environmental exposure probably differed from those of their parents and grandparents. 
This suggests that genetic susceptibility probably played a more important role than 
environmental factors in familial aggregation of these diseases.
In some families a change in the activity of the SOD1 gene on chromosome 21 is believed 
to play a role both AD and PD. 53, 54 Since different mutations in this gene are linked 
to ALS, 9 this raises the question of how the mutations affect neuronal degeneration, 
and which factors influence the preferential expression of the gene in a specific type of 
neurons. It also makes this gene a candidate for testing the mechanism of a shared genetic 
susceptibility to ALS, PD, and AD.
Familial co-occurrence of classical ALS and dementia (and possibly PD) may reflect 
pleiotropic expression of the same genetic predisposition, perhaps triggered by different 
environmental exposures. Families in which these disorders co-occur may form a distinct 
genetic subtype. It would be interesting to investigate whether, in some families with ALS 
and dementia or PD, all three disorders may be linked to the same genetic markers and, if 
so, to determine the factors responsible for variability in expression of clinical symptoms, 
whether genetic, environmental, or a combination. Our data suggest that further research 
into the common etiology of ALS, dementia, and PD may be fruitful, especially from a 
genetic point of view. 
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Increased co-occurrence of dementia 
and parkinsonism in the families of 
amyotrophic lateral sclerosis patients
D Majoor-Krakauer, WG Johnson, LP Rowland, R Ottman
Abstract
Genetic causes for amyotrophic lateral sclerosis (ALS) include disorders with familial 
co-occurrence of ALS, dementia and parkinsonism. We investigated co-occurrence of 
dementia and parkinsonism in the families of 140 pairs of ALS patients and controls. 
Familial aggregation of dementia and parkinsonism was doubled in families of ALS 
patients (odds ratio 2.5; p=0.096). Dementia in families of sporadic ALS patients increased 
risk for parkinsonism, suggesting a familial association between the three disorders. 
Introduction  
Amyotrophic lateral sclerosis is a neurodegenerative disorder characterized by a 
progressive deterioration of motor neuron functions. Mendelian inherited ALS, observed in 
approximately 10% of the patients is clinically and neuropathologically indistinguishable 
from sporadic ALS. During the last decade various gene defects have been identified 
in hereditary forms of ALS. In ALS without a clear-cut inheritance pattern various 
‘susceptibility’ genes have been identified. The hypothesis is that these ‘susceptibility’ 
genes have been reported which are thought to activate a cascade of neurodegenerative 
mechanisms by interaction with other low penetrant gene sequences or with environmental 
risk factors.1 
Our understanding of the molecular pathogenesis of ALS is further complicated by 
the existence of genetic disorders with overlapping clinical and pathological features 
of ALS, dementia and parkinsonism. Examples are the tauopathies, frontotemporal 
dementia with parkinsonism and amyotrophy linked to chromosome 17 (FTDP-17) 2 and 
the Guamianan type of ALS. 3 Other examples of familial aggregation of ALS, dementia 
of the frontotemporal type are characterized by ubiquinated, tau-negative intraneuronal 
inclusions. 4-6 The indications that ALS and extrapyramidal features are part of a multi-
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system disease process underlying motor neuron disease are accumulating. 7, 8 
In a previous study the occurrence of either dementia or parkinsonism was investigated 
in a large group of first- and second degree relatives of ALS patients and controls. The 
cumulative incidence of dementia to age 90 was two times higher in relatives of ALS 
patients than in relatives of controls. And the same was true for parkinsonism. 9 The 
current study aimed to determine whether occurrence of both dementia and parkinsonism 
is more frequent in the families of ALS patients.
Methods 
A case control study using the family histories of ALS, dementia and parkinsonism 
was carried out in 1156 siblings, parents and grandparents of 151 newly diagnosed ALS 
patients and 140 age and gender matched controls with 1102 relatives. Sixty percent of 
the participants were men, with a mean age of 60 years (range 21-86). (table 1) ALS 
patients and controls had the same mean number of siblings. Ascertainment of patients and 
controls, and data collection were published earlier. 9 All newly diagnosed patients had the 
diagnosis definite or probable ALS according to the El Escorial criteria of both upper and 
lower motor neuron signs. 
Table 1. Characteristics of familial and sporadic amyotrophic lateral sclerosis
(ALS) patients and controls.
Familial ALS Sporadic ALS Total ALS Controls
Total 7 144 151 140
Men 4 (57%) 86 (60%) 91 (60%) 83 (60%)
Mean Age (range) 59 (43-77) 60 (21-86) 60 (21-86) 59 (24-87)
Mean no. of siblings (range) 3 (1-8) 3 (0-13) 3 (0-13) 3 (0-11)
To reduce bias in participation the study objective was indicated as addressing the “causes 
of neurological diseases” without emphasizing genetics. Information about symptoms of 
ALS, dementia and parkinsonism was sought for each parent, sibling, and grandparent 
individually using a semi-structured interview. About one third of the medical records 
of relatives who were reported to be affected could be obtained for confirmation of the 
diagnosis. For the remaining relatives reported to be affected no medical records were 
available for review. The familial association between dementia and parkinsonism was 
examined by calculating the odds ratios for a family history of parkinsonism in families 
with dementia. This analysis was carried out separately within the families of ALS patients 
and controls. 
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To compare the co-occurrence of dementia and parkinsonism in the family we used 
a matched-pairs univariate logistic regression analysis of 140 pairs of ALS cases and 
matched controls, each case-control pair forming a cluster.
Results
We evaluated associations between parkinsonism and dementia within the families of 
ALS patients and controls. To do this, we estimated the odds ratios for a family history of 
parkinsonism in subjects with vs. without a family history of dementia. (table 2) In five 
families of ALS patients and two families of controls dementia was reported in several 
relatives. Whereas multiple cases of parkinsonism occurred in two families of sporadic 
ALS patients, none of the families of the controls had more than one case of parkinsonism. 
Table 2. Familial aggregation of dementia and parkinsonism in families of
ALS patients and controls
Number of Patients
Total
With a family history
of parkinsonism
Odds Ratio
(95% CI)
Sporadic ALS Patients
Family history of dementia 30 9 (30%) 11.8 (3.32-1.84)  p<0.001
No family history of dementia 114 4 (3.5%) 1.0 (reference)
Controls
Family history of dementia 20 4 (20%) 4.8 (1.21-8.68)  p=0.037
No family history of dementia 120 6 (5.0%) 1.0 (reference)
Patients with sporadic ALS who had a family history of dementia were almost 12 times 
more likely to have a family history of parkinsonism than those who did not have a 
family history of dementia (odds ratio 11.8; p<0.001). There were too few patients with 
familial ALS (n=7) to evaluate co-occurrence of dementia and parkisnonism in the family. 
Parkinsonism was reported in one of three families with familial ALS and dementia (OR 
1.5, 95% confidence interval 0.06-40.64). Controls with a family history of dementia were 
five times more likely to have a family history of parkinsonism than those without a family 
history of dementia (odds ratio 4.8; p=0.037). These data suggest a difference in familial 
aggregation of the diseases between 140 ALS patients and the matched control (odds ratio 
2.5; 95% confidence interval 0.8-8.3; p=0.096), considering the sample size of the present 
study. (table 3)
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Table 3. Co-occurrence of dementia and parkinsonism in the families of 140 pairs
of matched ALS patients and controls
Family history 
of dementia and 
parkinsonism
No family history 
of dementia or 
parkinsonism
Odds Ratio
(95% CI)
ALS patients*   10 (7%) 113 2.5 (0.8-8.3) p=0.096
Controls 4 (3) 114
*Sporadic and familial ALS 
Discussion
Genetic analysis of patients with Mendelian inherited ALS has led so far to the 
identification of four mutant genes: SOD1, alsin, senataxin and VAPB. In addition linkage 
to loci on chromosome 16q12, 18q21, 20p13 and 20q13 has been found for different 
autosomal dominant forms, an autosomal recessive form on chromosome 15q12-21 of ALS, 
and linkage for hereditary ALS with frontal lobe dementia has been assigned to a locus on 
chromosome 9q21. In an autosomal dominant form of parkinsonism (PARK8), mutations 
in the LRRK2 gene are associated with a wide spectrum of clinical features, including 
parkinonism with dementia or amyotrophy or both. 10
In our present epidemiological study we found a familial association between ALS, 
dementia and parkinsonism in families with sporadic ALS. The significant, twelve-fold 
increase in risk for parkinsonism in families of ALS patients with dementia points to a 
common genetic susceptibility and variable expression in a specific group of ALS patients. 
It is unlikely that co-occurrence of dementia and parkinsonism in ALS patient is due to 
bias, since a positive family history for other neurological diseases (multiple sclerosis, 
poliomyelitis and stroke) in ALS patients was similar to that in controls, irrespective a 
family history of dementia or parkinsonism.
Intrafamilial variability is characteristic of hereditary disorders associated with dementia, 
parkinsonism and amyotrophy. Although the molecular pathogenesis is not yet fully 
understood, the familial aggregation of ALS, dementia and parkinsonism might be the 
result of an interaction of a common genetic defect with other, low penetrant genetic factors 
and/or environmental influences leading to variable neurodegenerative mechanisms.
On the other hand, since dementia and parkinsonism are highly prevalent in the elderly 
and the difference between the ALS patients and controls in familial co-occurrence of 
these disorders in this epidemiologic study was not statistically significant, we cannot rule 
out that our observation occurred by chance. The results of epidemiologic studies on the 
occurrence of dementia in relatives of patients with Parkinson’s disease (PD) and that of PD 
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in relatives of patients with Alzheimer’s disease are inconsistent. 11 12 
The evidence for overlapping molecular features between ALS, parkinsonism and dementia 
is growing. For instance, the presence of tau protein accumulation in FTDP-17 and 
Guamanian ALS or ubiquitin reactive, tau negative pathology in patients with overlapping 
features of ALS and frontotemporal dementia. 4-8 Frontal dysfunction was found in a 
significant proportion (50%) of ALS patients. 13 
Our data suggest the existence of gene sequences predisposing to age related multisystem 
neurodegeneration and thus warrants further research for specific genes in ALS with co-
occurrence of dementia and parkinsonism. Exact clinical, genetic and neuropathological 
characterization is a prerequisite for a molecular identification to be meaningful.
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Environmental risk factors for 
amyotrophic lateral sclerosis
Cycas circinales: developing female megasporophylls, first with ovules
(above) and then with large seeds and new leaves (below),
from Rheede’s 1682 Hortus Indicus Malabaricus
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CHAPTER 5.1
Amyotrophic lateral sclerosis on Guam
Toward the 1940s an extremely high prevalence of ALS in the Chamorro population 
of the western Pacific island Guam attracted attention and was associated with another 
neurodegenerative disorder, the parkinsonism-dementia complex (PDC). 1 2 3 
The co-occurrence of ALS and PDC in patients and families was observed in a few other 
areas in the Pacific as well. 4
So far, no genetic causes for the ALS-PDC have been identified by analysis of the major 
ALS gene, copper –zinc superoxide dismutase (SOD1), or of apolipoprotein E and 
cytochrome debrisoquine hydroxylase genotypes. 5 Epidemiologic and genetic studies 
indicate that familial recurrence occurs more frequently (in 30-80%) in ALS/PDC 
compared to classical ALS, with a familial recurrence of 5-10%. 6-8
The incidence rate of ALS worldwide is 2-7/100,000 persons per year. In the period 
between 1950 -1964 an exceptionally high incidence rate of 50-100 per 100,000 population 
per year was observed on Guam. On average the age at onset of ALS in the Chamorro 
population was 10 years earlier than was the case of classic ALS. 1 From the late 1960s on, 
the incidence of ALS declined steadily to 3-7/100,000 per year for both sexes. 9, 10 In the 
same time the incidence of PDC on Guam decreased from 55 to 25 per 100,000 for men, 
and 23 to 21 for women, persisting at about 18 per 100,000 per year. In the same period the 
age of onset of ALS and PDC increased to that elsewhere. 11 
Clinically the Guamanian type of ALS is indistinguishable from classic ALS. The 
neuropathology of ALS/PDC, however, differs from that in non-Chamorro cases of 
ALS. 12 The neuropathologic hallmark of ALS /PDC is abundant neurofibrillary tangles 
consisting of intracytoplasmic filamentous tau inclusions in widespread regions of the 
central nervous system, the brainstem and spinal cord. The neurofibrillary tangles exhibit 
very similar biochemical and ultrastructral properties of their phosphorylated tau protein, 
to those of Alzheimer’s disease (AD), but the specific laminar and regional cortical 
distribution of the neurofibrillary tangles is different from that seen in AD. 13-15 In contrast 
to the frontotemporal dementia and parkinsonism complex (FTDP-17), a clinically similar 
tauopathy, where mutations in the tau gene generally result in overexpression of the four-
repeat tau protein isoforms, mutations of the tau gene were not found in ALS/PDC. 16-18 
The endemic occurrence of ALS/PDC in Guam and its dramatic decline occurring within a 
couple of decades, cannot be explained by a change in genetic susceptibility because of the 
population composition.
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Furthermore a high incidence of ALS/PDC in immigrants, from areas where risk for ALS 
is low, supports an environmental risk factor, possibly in interaction with a more prevalent 
genetic susceptiblility. 19-22 
Because the geographical incidence rates of ALS/PDC are correlated with the consumption 
of food containing the seed of the locally growing cycad palms, Cycas Circinalis, much 
effort was spend on studying the neurotoxic components of the sago fruit, to understand the 
underlying pathogenic mechanism. 23
The traditional procedure used to prepare cycad seeds for consumption involves an 
extensive detoxifying soaking. The soaking diminishes the residue of toxic components 
like cycasin and the aminoacid BMMA 24 but not that of other, water insoluble toxins, like 
sterol beta-d-glucoside. The feeding of washed seeds containing this glucoside to mice 
inflicted neurologic deficits consistent with the clinical features of ALS/PDC as well as the 
formation of neurofibrillary tangles. 25, 26
A B
C D
A. Immature seed (arrow) on seed-bearing megasporophylls of Cycas circinalis.
C. Two mature seeds of the type used to prepare flour.
B. Mature seed, split seed showing the starchy white endosperm and the latter removed and soaking in water to 
leach out water-soluble poisonous principle.
D. Traditional method of grinding the washed and sun-dried cycad seed endosperm (arrrow) to produce flower 
used in tortillas and other local foodstuffs.
From: Peter S. Spencer, Le Journal Canadien de Sciences Neurologiques, 1987;14:347-357
Guam ALS/Parkinsonism-Dementhia: A Long-Latency Neurotoxic Disorder Caused by “Slow Toxin(s)” in Food.  
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Also, recently additional insight in the mechanism behind exposure to toxic components 
of cycads on Guam was gained by the discovery that the Chamorro population of Guam 
probably ingested large quantities of cycad toxins indirectly by eating flying foxes. 
The indigenous flying foxes apparently fed on cycad seeds and were found to contain 
extraordinarily high concentrations of the toxic component BMMA of the cycad seeds. The 
decline in disease has been attributed to a change in consumption patterns. 27, 28
Therefore the most important risk factors for ALS in Guam seem to be the predisposition 
in the Guamanian population to form neurofibrillary tangles and the ingestion of cycad. On 
one side experiments with transgenic mouse models suggest a dose-dependent association 
between overexpression of human tau protein in mice and an age-dependent phenotype 
similar to ALS/PDC. 29 On the other, there is evidence that at autopsy the characteristic 
neurofibrillary tangles occur in a large percentage of the adult, neurologically intact, native 
Guamanian population.13, 30-32 The prevalence of the intraneuronal tau accumulations in 
the Chamorro population seems to remain high, despite the declining incidence of ALS/
PDC. It seems that this tauopathy in the Chamorro population is insufficient by itself to 
cause symptoms and exposure to additional less prevalent risk factors, for instance the 
consumption of food containing neurotoxic components may trigger the neurodegenerative 
process.
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A flying fox (Pteropus mariannus) eating the seeds of 
a cycad (Cycas rumpii) in Guam.
Photograph by Merlin Tuttle, Bat Conservation 
International. From: Cox P.A. and Sacks O.W. Cycad 
neurotoxins, consumption of flying foxes, and ALS-
PDC disease on Guam. Neurology, 2002;58:956-959.
Preparing cycad flour and tortillas. From “Voyage autour du monde” by L. de Freycinet.
in Stelle J.C. and Guzman T. Observations about amyotrophic lateral sclerosis and the 
parksinonism-dementia complex of Guam with regard to epidemiology and etiology.
John C. Steele and Tomasa Guzman. The Canadian Journal of Neurological Sciences 
1987;14(3 suppl) :358-362
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A flying fox of the genus 
Pteropus prepared for 
consumption at a Chamoro 
feats in Guam. After boiling 
in coconut milk, the animal is 
consumed in its entirity.
Photograph by Merlin 
Tuttle, Bat Conservation 
International. From: Cox 
P.A. and Sacks O.W. Cycad 
neurotoxins, consumption of 
flying foxes, and ALS-PDC 
disease on Guam. Neurology, 
2002;58:956-959.
An advertisement for 
imported flying foxes in 
Guam. After the Guamanian 
species vanished, 18,000 were 
imported from Samoa during 
a 3-year period.
Photograph by Merlin 
Tuttle, Bat Conservation 
International.
From: Cox P.A. and Sacks 
O.W. Cycad neurotoxins, 
consumption of flying foxes, 
and ALS-PDC disease 
on Guam. Neurology, 
2002;58:956-959.
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Introduction 
Between 1940 and 1965 an unusually high incidence of amyotrophic lateral sclerosis 
(ALS), with co-occurrence in patients and families of a parkinsonism-dementia complex 
(PDC), was observed in the Chamorro population of Guam. So far, no genetic causes for 
ALS/PDC have been found. The increased risk of ALS in migrants to and from Guam 
suggests a combined effect of an environmental exposure and a genetic susceptibility. 1, 2 
The declining incidence of ALS on Guam has been attributed to changes in the consuming 
patterns of food containing the seed of the locally growing cycad palms. These seeds were 
either processed traditionally in cycad flour or ingested indirectly by the consumption of 
indigenous flying foxes. These foxes were foraging on the cycad seeds and are supposed to 
contain high concentrations of the neurotoxic components of the seeds. 3, 4 
We had information on residence on Guam in a previously conducted case-control study of 
ALS and we could therefore investigate the possibility that residence in Guam contributed 
to risk for ALS in citizens of the United States. 
Methods
The study population consists of 140 pairs of ALS patients and neurologic controls, 
matched for age (+ 5 years), gender (83 pairs of men and 57 pairs of women) and insurance 
status. Participants were patients newly diagnosed with ALS patients between 1989-1991 
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at the Neurological Institute Columbia-Presbyterian Medical Center in New York. 5 The 
family histories of ALS, dementia and parkinsonism, occupational and medical histories 
were ascertained in a semi-structured interview. Information on residence outside the 
continental United States for a period of at least one month (place, date and the duration 
of the stay) was recorded, without alluding to specific places or continents. Information 
on military service was obtained, including the date of conscription, a job description, 
whereabouts and serious health problems during military service. To investigate the 
association between Guam and ALS, a matched-pairs exact conditional logistic regression 
analysis was performed, each case-control pair forming a cluster. Multivariable analysis 
was performed to control for confounding.
 
Results and Discussion
The results show a significant association between short residence on Guam and ALS (OR 
8.0, 95% CI 1.07-355). (Table) This association remained in multivariable analysis with 
age, gender, education, a family history of ALS, dementia or parkinsonism, enrolment 
and duration of military service, exposure to pesticides, and trauma (OR 9.40, 95% CI 
1.08-81.91, p=0.04). The mean age at diagnosis of patients who were on Guam was not 
different (66 years, range 47-81) from patients who had not been on Guam (60 years, range 
21-86)(p=0.6). ALS was not associated with residence in Central or South America, the 
Philippines, New Guinea or other areas in the South Pacific. Neither was ALS associated 
with military service. There was no difference in year of enrolment (OR 1.0, 95% CI 0.87-
1.27) or the duration of military service (OR 1.0, 95% CI 0.93-1.23). None of the ALS 
patients were hospitalized, seriously injured or had a blood transfusion on Guam.Of the 
nine patients six were on Guam during their military service. One ALS patient was one 
month, seven were two months and one was fifteen months on Guam. The mean time 
between the end of the stay on Guam and the diagnosis of ALS was 43 years (range 27-57).
Before we can accept the association of short residence on Guam with ALS, 
methodological issues have to be addressed.The goal of the original study did not specify 
Guam as a putative risk factor. Therefore selection bias related to residence on Guam seems 
unlikely. For the same reason we did not collect further information e.g. on eating habits 
during the stay on Guam. It would have been intriguing to know if patients had traditional 
cuisine containing cycad seeds.
Because the Neurologic Institute was not known for an interest in the association between 
ALS and Guam it is unlikely that preferentially referral of patients who stayed on Guam 
biased the outcome of this study. However, given our study design we can not fully rule out 
selection or information bias have played a part.
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Table. Former residence on Pacific Islands among Amyotrophic Lateral Sclerosis 
(ALS) patients and controls.
ALS
N=140
Controls
N=140
Odds Ratio 
(95% CI)
p-value
Guam   9 1
8.0
(1.07-355)
0.04
New Guinea / South 
Pacific*
10 8
1.3
(0.26-7.47)
0.94
Military service: 54 53
0.8
(0.54-1.34)
0.49
Start* *Mean (range)
1942
(1939-1975)
1942
(1940-1970)
-
Duration*** Mean (range) 
years
3 years
(1-39)
4 years
(1-18)
-
Excluding Guam ** Forty (28%) ALS patients and thirty-three (23%) controls started 
military service before the end of World War II, twenty (14%) ALS patients and twenty 
(14%) controls after 1945 (p=0.85). ** *(p=0.53) Wilcoxon signed ranks test.
Despite the small sample size of this study we detected an association where two larger 
studies did not. The time from exposure to ascertainment in the two earlier studies was 
shorter, 16-25 years and 15-27 years, respectively, than in the present study (43 years, range 
27-57). 6, 7 This could indicate that one of the key characteristics of the exposure occurring 
during the period of endemic ALS on Guam, is the long delay in clinical expression. In 
conclusion, our epidemiologic data bolster the vision that exposure to slow acting toxic 
agents are important in the pathogenesis of ALS, most likely in combination with a genetic 
predisposition. 
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Summary
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by 
progressive loss of upper and lower motor neurons leading to severe disability and early 
death. The main etiologic hypothesis involves the interaction of specific environmental 
exposures with distinct genetic susceptibilities for the majority of ALS. The current 
case-control study of 140 pairs of ALS patients and controls, matched for age, gender and 
socioeconomic status, aims to re-investigate previously reported risk factors for ALS and to 
analyze the interactive effect of each of these proposed risks with a genetic predisposition 
to neurodegeneration, defined by a family history of amyotrophic lateral sclerosis, dementia 
or parkinsonism. We collected information on antecedent medical histories (specific 
infectious diseases, diabetes, autoimmune disorders, surgery and injuries), exposure to 
animals or to specific environmental toxins (pesticides, aluminum, lead and others), the 
occupational histories, lifelong smoking habits and the consumption of alcoholic beverages.
In multivariable analysis ALS was associated with a history of tuberculosis (odds ratio 
8.16, 95% CI 0.91-73,08, p=0.06), exposure to pesticides (odds ratio 2.21, 95% CI  0.92-
5.36, p=0.08) and previous residence on Guam (odds ratio 9.5, 95% CI 1.08-81.91, p=0.04). 
Interactive effects of exposures with a family history of neurodegenerative disorders was 
not detected.  
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Introduction
Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, is characterized by a 
progressive loss of motor neurons in the cerebral cortex, brainstem, and the anterior horn 
cells of the spinal cord. In most patients onset occurs in middle life and death is attributed 
to respiratory failure 3-5 years after onset. Amyotrophic lateral sclerosis is predominantly 
(80%) a sporadic disorder. Established risk factors for ALS are age, male gender and a 
growing number of genetic defects involving different molecular pathways. The age at 
onset, the survival of ALS and the occasionally observed extrapyramidal pathology in 
some ALS patients, is variable both within families with specific genetic forms of ALS, 
and in patients with identical genetic defects from different families with ALS. 1, 2 These 
observations strongly suggest that the effect or expression of genetic defects can be 
modulated by epigenic or environmental factors. 
Small clusters of ALS, related to shared professional or residential proximity, have been 
reported throughout the world. 3-7 Similarly, the observation of conjugal ALS strongly 
suggests etiologic factors in the environment or in lifestyles. 8, 9 The small number of 
affected individuals in these clusters complicates differentiating between a common 
exposure, transmission of a causal agent or pure coincidence. Nevertheless, the clusters 
keep the discussion alive about potential environmental causes for ALS.  
Previous epidemiological studies investigated potential risk factors including 
environmental exposures related to residence, occupation or lifestyle, physical trauma, 
and medical histories. 10, 11 The current study was conducted to re-investigate alleged 
environmental risk factors for ALS and to analyze a possible interactive effect of each of 
these risk factors with a genetic predisposition to neurodegeneration.
Subjects and Methods
Study population
The study population consists of 140 pairs of ALS patients and controls, matched for age 
(+ 5 years), gender (83 pairs of men and 57 pairs of women) and insurance status, as a 
proxy for socioeconomic status. Participants were newly- diagnosed patients with ALS, 
ascertained from the Neurological Institute, Columbia Univeristy Medical Center, New- 
York, in the years 1989-1991. The clinical diagnosis of ALS was restricted to patients with 
both upper (Babinski sign or clonus) and lower (weakness, wasting, fasciculation) motor 
neuron signs. The patients would therefore correspond to those with definite or probable 
ALS according to the El Escorial criteria (which were not introduced until 1994; after our 
patients had been selected).
 For each ALS patient, a control was selected from patients admitted for stroke 
or scheduled for EMG on the nearest day to the ALS patient, who matched the ALS case 
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by age (±5 years), gender, and payment status (Medicaid or Medicare vs. private). If the 
first selected control refused or was unable to participate, we selected the next patient 
who matched the case. This procedure was repeated until a suitable control was found. 
We excluded candidate control subjects if their discharge diagnoses indicated any kind of 
dementia, parkinsonism, hereditary neuropathy, spinal muscular atrophy, or motor neuron 
disease. The diagnoses of the controls included: stroke (23%), radiculopathy or spinal cord 
compression (36%), peripheral (sensory or motor) neuropathy (23%), multiple sclerosis 
(4%), and myopathy (9%). In the remaining 5%, no neurological abnormality was detected. 
Exposure assessment
Participants where invited to participate in an interview for a research study of neurological 
diseases. A semi-structured questionnaire was administered to ascertain detailed 
information on the family histories, and the medical, occupational, and residential histories. 
Questions were read to the participant and answers recorded by the interviewer on the 
standard interview form. Interviews were administered in person during the hospital 
admission or outpatient consultation (50%) or administered by telephone within three 
weeks after discharge or outpatient consultation. There was no difference between the ALS 
patients and controls in terms of the proportion interviewed in person (ALS patients 50%; 
controls 40%) or by telephone. 
Family history
For each relative (sibling, parent and grandparent) a separate questionnaire was 
administered with questions in non-technical language addressing Alzheimer’s disease, 
dementia or symptoms of irreversible cognitive decline in relatives. Similarly, the diagnosis 
of Parkinson disease or symptoms of parkinsonism and symptoms of ALS was sought for 
each sibling, parent and grandparent individually. Offspring were excluded from the study 
because we assumed that the offspring would not yet have reached the age periods at risk 
for ALS, dementia or parkinsonism. About one third of the medical records of relatives 
who were reported to be affected were obtained for confirmation of the diagnosis. The 
family history of ALS, dementia and parkinsonism was defined as positive if at least one 
relative was reported affected. The size of the family is determined by the number of 
siblings, and was similar for ALS patients and controls (mean number of siblings was 3). 
Familial ALS was reported in seven (5%) ALS patients; none of the controls reported a 
relative with ALS. In this study risk for ALS was significantly associated with a family 
history of neurodegenerative disorders (ALS, dementia and/or parksinonism).
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Medical history
The interview included questions on the lifetime occurrence of the following medical 
conditions: diabetes, cancer, eczema, asthma, rheumatoid arthritis, ulcerative colitis and 
multiple sclerosis (table 1). We asked if the participants had suffered injuries such as 
fractures, muscle lacerations, burns or electrical shocks. Details were ascertained from 
the injuries and we subsequently classified the injuries according to the affected part of 
the body (head or spine, abdomen or chest and limbs). We recorded whether an injury 
necessitated medical attendance or hospitalization. We asked if trauma resulted in loss of 
consciousness and the number and duration of these events and the age at the time of each 
event was recorded. All surgical procedures or blood transfusions were recorded separately. 
The medical records were used to validate the medical histories.
Infections
To complete the medical histories questions were asked about the occurrence of specific 
infectious diseases (poliomyelitis, meningitis/encephalitis, mumps, shingles, herpes, 
tuberculosis, rubella, chicken pox, whooping cough and hepatitis) (table 2).
 
Occupational history
A lifetime occupational history was ascertained and for each occupation a job description, 
the period spent on each job were recorded separately (table 3). The occupations were then 
grouped into ten different categories: white collar (office workers, teachers, salespersons, 
clergymen, musicians, psychoanalyst); medical (physicians, nurses, dentists); food and 
meat handling (chefs, butchers); professions with high exposure to electromagnetic 
fields (electricians, powerplant operators, radiologists); jobs with exposure to chemical 
substances and solvents (dry cleaning, chemist, photographer, painter, tobacco industry, 
hairdressers); jobs requiring heavy physical work (construction workers, laborers, movers), 
mechanics, and jobs in textile industry. Furthermore, we asked whether the patient had ever 
worked with a jackhammer or any other kind of tool that uses compressed air. Information 
on military service was obtained, including the date of conscription, a job description, 
whereabouts and serious health problems during military service, as described in the 
previous section of this chapter. The interview also included questions about level of 
education. Physical activity in youth was assessed by participation in physical education 
classes. 
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Toxic exposures
We inquired about occupational or residential exposure to radioactivity, lead, mercury, 
selenium, copper, mercury, aluminum, manganese, nickel, plastic manufacturing, arsenic, 
leather, hides, pesticides, petroleum products, gas or oil (table 4).
Exposure to animals
The patients were asked if they had ever lived with a household pet or if they had ever 
worked with or close to farm animals or to other animals, and for how long (years) the 
exposure lasted. The animals were grouped into one category of domestic pets (dogs, cats, 
guinea pigs), one for birds or poultry, one for cow, horse, or sheep and a separate category 
was created for other household pets (fish, turtle, snake and lizards) that we will further 
refer to as ‘fish’ (table 5).
Lifestyle
Information was collected on lifelong smoking habits of cigarettes, cigars and pipe. For 
persons who reported smoking, the age at which they started smoking, the number of 
cigarettes a day smoked and the number of years they had been smoking was recorded. The 
average consumption per week of glasses of beer, wine or hard liquor was recorded. The 
patients were also asked whether they had used illicit drugs (marijuana, hashish,cocaine, 
heroin, morphine, LSD) more than 10 times during their entire life. 
The interview included questions about level of education, rural residence and the nature 
of the farms (cattle breeding, dairy, poultry, agriculture). When cattle- breeding or dairy 
farming was reported, the information was registered as exposure to cattle (see above). 
Residence outside the United States for more than one month was recorded by country, 
duration (months) and date (year). The interview also addressed possible prenatal 
exposures, by requesting information on the health condition of both parents in the period 
around the birth of the participant, including information on smoking habit, alcohol use, 
and medical treatments. 
Statistical analysis
We used univariable conditional logistic regression analysis to obtain odds ratios and 
their confidence intervals for each exposure. Although we had probed for information on 
the duration of the exposures, for many variables this information was missing for too 
many subjects to add any meaningful results. Nonparametric paired tests were used for 
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comparison of the exposure variables between cases and matched controls. The McNemars 
test was used for univariable analysis of categorical variables and the Wilcoxon signed rank 
test for univariable analysis of continuous variables. Variables missing data for greater than 
10% of subjects, or with p-values greater than 0.3 in the univariable test were not included 
in further analysis. For each of the remaining variables we separately tested for interaction 
with a family history of neurodegenerative disease (ALS, dementia or parkinsonism).
For the remaining variables multiple conditional logistic regression analysis was performed 
with the case control pair as stratum and the exposures as independent variables. Family 
history of neurodegenerative disease was also included as a covariate. Further selection 
was made using backward stepwise methods, retaining variables with a p-value below 0.15 
in the logistic regression model. Independent variables (exposures) that did not contribute 
to the variance were excluded from the analysis (and recalculation was performed).
Age and gender were included in the model as a continuous variable to control for any 
residual confounding not accounted for by the matching of cases and controls. Given the 
potential for confounding education was also included as a covariate in the regression 
analysis, although its inclusion had little effect on the relative risk estimates. 
Results
Of the 140 matched pairs 84 (60%) were male. Familial recurrence of ALS was reported 
in seven ALS patients (5%) and not in controls. The mean age of men in this study was 60 
years (range 22-82) and of women 62 years (range 24-88). In familial ALS the mean age of 
men was 55 years (range 44-74) and of women 64 years (range 53-78). A family history of 
ALS, dementia or parkinsonism was a significant risk factor for ALS (odds ratio 2.06, 95% 
confidence interval 1.12-3.83), independent of the age of the subject (p for interaction 0.78).
Medical history
From the medical conditions only diabetes was reported differently by ALS patients and 
controls. Diabetes was associated inversely with ALS. This association was not apparent 
when controls who were diagnosed with stroke were excluded from the analysis. (table 1) 
No evidence for an association with autoimmune disorder or malignancies was found. ALS 
patients reported more injuries, in particular injuries of the head and spine and fractures of 
other parts of the body that required hospitalization. 
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Table 1. Number of ALS cases and controls, and univariable odds ratios for 
medical histories
 
ALS Controls
Odds 
ratio
CI (95%)
Diabetes 10/140 22/140 0.36 0.15 0.87
Diabetes * 10/139 17/107 0.43 0.16 1.11
Rheumatoid arthritis 24/140 19/140 1.38 0.67 2.82
Eczema 20/140 20/140 1.0 0.51 1.05
Asthma 39/140 38/140 1.03 0.62 172
Ulcerative colitis 8/140 8/140 1.0 0.37 2.66
Carcinoma 21/140 17/140 1.33 0.63 2.81
Multiple sclerosis 1/140 5/140 0.20 0.02 1.71
Surgery 113/140 117/140 0.78 0.40 1.55
Blood transfusions 22/140 25/140 0.9 0.47 1.70
Injuries: 78/140 69/140 1.34 0.81 2.23
   medical treatment 64/140 59/140 1.01 0.78 1.32
   hospitalization 32/140 24/140 0.82 0.54 1.24
   unconsciousness 7/140 7/140 1.0 0.35 2.85
   head or spine 20/140 14/140 1.60 0.72 3.52
   chest or abdomen 2/140 2/140 1.0 0.14 7.09
   limb 73/140 65/140 1.27 0.78 2.07
   muscle 28/140 27/140 1.05 0.55 2.01
   fracture 50/140 39/140 1.16 0.83 1.60
   burn 2/140 2/140 1.0 0.14 7.09
   electrical shock 1/140 2/140 0.5 0.04 5.51
* excluding controls with stroke from the analysis
 Infections
A history of tuberculosis was associated with an increase in risk for ALS (table 2). In 
multivariable analysis the association with tuberculosis remained. None of the patients 
or controls with a history of tuberculosis reported living or working on a dairy or 
cattlebreeding farm. A history of poliomyelitis was more frequent in ALS patients, but was 
not associated with ALS in the multivariable analysis. Neither did a history of any viral 
infection affect risk for ALS (odds ratio 0.61, 95% CI 0.31-1.23).
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Table 2. Number of ALS cases and controls, and univariable odds ratios for 
specific infectious diseases
 
ALS Controls Odds ratio     CI (95%)
Bacterial
Tuberculosis 7/138 1/139 7.00 0.86 56.89
Whooping cough 31/116 40/123 0.71 0.37 1.39
Viral
Poliomyelitis 6/140 3/138 2.00 0.50 8.00
Shingles 12/140 15/138 0.77 0.34 1.75
Hepatitis 4/135 8/136 0.50 0.15 1.66
Rubella 43/116 41/125 1.53 0.80 2.94
Measles 71/113 78/126 0.95 0.51 1.78
Chicken pox 85/121 97/131 0.83 0.46 1.51
Table 3. Number of ALS cases and controls, and univariable odds ratios 
for occupational histories
ALS Controls Odds ratio CI (95%)
White collar 114/140 92/140 3.20 1.57 6.50
Medical 7/140 12/140 0.50 0.17 1.46
Food handling 9/140 5/140 1.80 0.60 5.37
Electricity 3/140 7/140 0.42 0.11 1.65
Electromagnetic 
fields
4/140 7/140 0.57 0.17 1.95
Chemical 14/140 13/140 1.08 0.49 2.37
Textile 6/140 4/140 1.50 0.42 5.31
Mechanic 14/140 15/140 0.92 0.43 1.97
Plastic 3/140 3/140 1.0 0.20 4.95
Radioactivity 1/140 0/140
Physical labor 21/140 25/140 0.78 0.40 1.55
Jackhammer 15/140 8/140 2.0 0.80 4.95
Farmer 31/140 32/140 0.84 0.56 1.70
  Cattlebreeding 3/140 2/140 1.50 0.25 8.97
  Dairy 8/140 9/140 0.87 0.31 2.41
  Poultry 2/140 0 65.28 0.001 5658
  Agriculture 8/140 11/140 0.72 0.29 1.80
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Occupational history
We found an excess of ALS with occupations that were classified as ‘white collar’. The 
professions that involve physical labor was less frequent in ALS patients. (table 3) None 
of the other occupations were associated with ALS; including professional exposure to 
electromagnetic field (to exposure to electricity or radioactivity and reported electrical 
shocks), or professions with exposures to chemicals and solvents, professions handling 
leather or hides or the processing of petroleum-, gas- or oil products. Farming was reported 
similarly in ALS patients and controls. 
Toxic exposures
The use of pesticides was significantly associated with ALS. (table 4) The association with 
pesticides remained in the multivariable analysis. (table 7) Exposure to pesticides was not 
associated with agricultural farming (p=0.82) nor with exposure to horses, cow or sheep 
(p=0.18); exposure to pesticides was reported in 3/8 ALS patients involved in agriculture 
(Fisher exact p=0.21) and in 2/11 controls involved in agriculture (Fisher exact p=0.42). 
Exposure to pesticides was reported in 5/21 ALS patients with exposure to horses, cow or 
sheep (Fisher exact p=0.34) and 4/16 controls (Fisher exact p=0.02). Reported exposure to 
lead, copper, mercury, aluminum, manganese, nickel, magnesium, petroleum products, gas 
or oil and heavy metals were not associated with an increase in risk for ALS. (table 4)
Table 4. Number of ALS cases and controls, and univariable odds ratios for 
toxic exposures
 
ALS Controls Odds ratio CI (95%)
Pesticides 23/139 11/137 2.33 1.06 5.09
Lead 20/135 18/136 1.18 0.61 2.30
Copper 17/137 17/137 1.0 0.47 2.09
Mercury 10/138 6/135 1.66 0.60 4.58
Heavy Metals 16/139 11/137 1.50 0.67 3.33
Aluminum 13/139 12/138 1.09 0.48 2.47
Manganese 8/139 7/138 1.14 0.41 3.15
Nickel 8/138 5/137 1.60 0.52 4.89
Magnesium 8/138 7/138 1.14 0.41 3.15
Arsenic 2/139 6/138 0.33 0.67 1.65
Leather/hides 4/140 4/139 1.0 0.25 3.99
Petroleum/gas/oil 15/139 12/138 1.3 0.57 2.96
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Exposure to animals
The bivariate analyses of contacts at home or at work, including living on a farm, with 
horses, cow or sheep showed a significant association. (table 5) The association with 
exposure to horse, cow or sheep did not remain in the multivariable analysis.(table 7) There 
was no report of tuberculosis in any of the persons exposed to cattle (including the subjects 
who lived or worked on dairy or cattle breeding farms). The risk for ALS was not increased 
by exposure to common household pets, birds and/or poultry, or other pets (turtles, fish, 
snakes). (table 5) 
Table 5. Number of ALS cases and controls, and univariable odds ratios 
for exposure to animals
ALS Controls Odds ratio CI (95%)
Horses, cow or sheep 16/140 7/140 2.80 1.01 7.77
Birds 19/140 17/140 1.18 0.53 2.64
Fish 9/140 6/140 1.50 0.53 4.21
Pets 103/140 106/140 0.89 0.52 1.53
Lifestyle
Neither smoking nor alcohol consumption was associated with ALS. (table 6) The data 
concerning the health and medication of the parents, and a job-description of the parents 
during the pregnancy were insufficient for analysis. The results of the analysis of stay 
outside the US for a period of more than six months, the information on having been in 
military service and in particular the significant association with previous residence on 
Guam were presented in a separate report.
Table 6. Number of ALS cases and controls, and univariable odds ratios for lifestyle
ALS Controls Odds ratio CI (95%)
Smoking* 92/140 89/140 1.13 0.64 2.01
Alcohol consumption (mean number of 
glasses a day)**
0.9 (0-15) 1.1 (0-14) 1.01 0.97 1.03
Soft drugs (marijuana, hashish) 6/140 10/140 0.5 0.15 1.66
Hard drugs+ (cocaine, heroin, LSD) 3/140 2/140 2.0 0.18 22.05
*ever smoked;  ** beer, wine or hard liquor; + used hard drugs more than 10 times.
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Interaction with family history of ALS, dementia or parkinsonism
We found a significant interaction between a family history of neurodegenerative disease 
and the exposure to copper (p=0.08), living on a dairy farm (p=0.07) and physical 
education in youth (p=0.04).
Table 7. Multivariable Model.*
Odds Ratio CI (95%) p-value
Tuberculosis 8.16 0.91 73.08 0.06
Pesticides 2.21 0.91 5.36 0.08
Jackhammer 2.23 0.84 5.92 0.11
Guam 9.40 1.08 81.91 0.04
  
* Adjusted for age, gender, education, family history of ALS, dementia or parkinsonism, 
exposure to cattle (horse, cow or sheep), dairy or agricultural farming, a history of 
fractures, injury to head or spine with or without unconsciousness, and physical labor.
Discussion
This case-control study was an exploratory approach to confirm previously reported risk 
factors for ALS. Our study supports the hypothesis that exposure to pesticides, a history 
of tuberculosis, previous residence on Guam and a family history of ALS, dementia or 
parkisnonism are associated with ALS.
Before we can accept these findings the following methodologic comments have to be 
made. Three aspects of our study design were intended to reduce bias. First, we avoided 
ascertainment or selection bias by describing our study objectives very generally when 
inviting subjects to participate. This should have reduced the possibility of selective 
participation of ALS with specific antecedent medical conditions or other presumed 
risk factors. Second we attempted to avoid a general problem of the case- control study, 
the recall or information bias, by selecting controls who were hospitalized because of 
severe neurologic illnesses, in whom the severity of their disorder might have evoked a 
level of concern comparable to that of the ALS patients about the possible causes of their 
neurologic problems. This should have minimized the differences between patients and 
controls in recall of antecedent events. Third, to reduce reporting bias further we use 
a very structured approach to obtain information on the exposures. The association of 
specific exposures with ALS depends on the method of exposure assessment. We have 
attempted to reduce information bias of occupational histories by using job titles and job 
descriptions to characterize occupations at increased risk for specific exposures. However 
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these procedures cannot prevent potential misclassification of true exposure. In absence 
of direct measurements of exposure in this study, self- reported information on exposures 
might have lead to misclassification bias. The absence of strong associations with ALS 
for instance with exposure to lead or aluminum, for which well known hypothesis exist, 
gives some assurance that over-reporting by cases was not a major source of bias in 
exposure assessment. Furthermore, considering a broad range of different risk factors in a 
multivariable analysis decreased risk for confounding in this study. 
We did not find interactions with a family history of ALS, dementia and parkinsonism 
because the statistical power was probably diminished with the available sample size.
Our data suggest an association with a history of tuberculosis. Few preliminary data exist 
on the association of tuberculosis and ALS. Some studies suggested that ALS is associated 
with an increased milk ingestion, especially in the youth. 12, 13  In our study living on a 
dairy or cattle farm was not associated with the transmission of tuberculosis.
Several explanations could be considered for the association with tuberculosis: a long-
term neurotoxic effect of a tuberculosis infection or, a neurotoxic effect of the antibacterial 
medication, a tuberculosis infection mediated immune respons involving antibodies against 
motorneurons, or a common (immunologic) increased susceptibility for tuberculosis and 
ALS. 
This study confirmed an association with exposure to pesticides. 14, 15  This association 
was not explained by more ALS patients than controls involved in agricultural farming, 
or exposed to cattle, horses or sheep. The association of pesticides, agricultural chemical 
or insecticides and ALS has been investigated in several studies, some showing a modest 
association with ALS. 16-18 In addition, a cohort study found an increase of ALS in workers 
in a chemical industry involving exposure to pesticides. 19-20 
The association of occupational pesticide exposure with Parkinson disease suggests 
a neurodegenerative effect of pesticides, particularly in combination with a genetic 
predisposition to neurodegeneration. 21, 22, 23  Our results are not consistent with the idea 
that motor neuron disease is a delayed sequel to infection with poliomyelitis or other 
infections. 24-27 Similarly, reports of ALS after a poliomyelitis infection are not supported 
by epidemiological studies, 28-30 although one study reported that DNA polymorphisms of 
the poliovirus receptor in cell cultures allowed persistent viral infection, and in humans 
the same polymorphism were associated with persistent poliomyelitis infection in ALS and 
progressive spinal atrophy. 31 
Our dat do not support that cattle farmers and sheperds have a higher risk for ALS.32
Since the legendary baseball player Lou Gehrig ALS was diagnosed with ALS, sport- 
related vigorous premorbid physical activity has been hypothesized, but has never been 
proven, to be a risk factor for ALS. 33 In this study risk of ALS was not affected by 
participation in sports at school. On the other hand, many types of sports predispose to 
injuries and fractures and many studies found that these types of injuries might play a role. 
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33-36 An increase of dementia in people suffering repeated head injuries suggested a dose 
dependent relation in neurologic trauma and neurodegeneration. 37 We could not detect a 
relation with injuries, although there was a discrete association with injuries particularly to 
head and spine, and in the number of fractures before the onset of neurologic symptoms in 
ALS patients. However, our data do not support the hypothesized association of working 
with a jackhammer or any other kind of tool that use compressed air. 7, 12 Our data also do 
not support an association with smoking. 38-40
We found a protective effect of diabetes mellitus for ALS in the current study, partly 
because we included stroke patients as controls, for which diabetes is an acknowledged 
risk factor. When the stroke patients were excluded from the control group the protective 
effect of became smaller. On the other hand, the protective effect could correlate with a 
loss of the neuroprotective vascular endothelial growth factor protein (VEGF). 25-27, 41 Loss 
of these neuroprotective properties of the VEGF protein are associated with ALS, 42, 43 and 
in patients with diabetes mellitus the over-expression of the VEGF gene in the neuronal cell 
bodies and axons possibly enhance the normal neuroprotective functions of this protein. 
The overrepresentation of ‘white collar’ professions in ALS patients in this study 
probably reflects a bias in ascertainment of ALS patients with easier access and particular 
knowledge of the ALS referral center at the Neurological Institute. 
This referral bias makes it hard to draw conclusions about other occupational risk for ALS 
in this study. 
Genetic causes play a major role in the etiology of ALS. During the last decade various 
gene defects have been identified in mendelian inherited ALS. Although the exact 
pathologic mechanism of these genetic defects are not yet fully understood, similar 
disruptions of various biochemical pathways, may play a role in sporadic ALS as well. 
Furthermore, various ‘susceptibility’ genes have been reported in sporadic ALS. 44 The 
hypothesis is that these ‘susceptibility’ genes may act by interaction with other low 
penetrant gene sequences or with environmental risk factors. 
Addressing the genetic complexity of sporadic ALS in search of gene-environment 
interaction poses a major challenge. It is tempting to believe that large studies collecting 
data on genetic variation and exposure of potential environmental risks will eventually 
permit proper analysis of gene-environment interaction in ALS.
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Introduction
During the last decade, genetic approaches to the study of ALS have resulted in new 
insights in the etiology of neurodegeneration. In a small fraction of patients with this 
most frequent paralytic disease in adults, defects in genes were identified, which cause 
intracellular protein accumulation, mitochondrial dysfunction, enhance excitotoxicity, or 
decrease axonal transport in motor neurons. 1
However the loss of motor neurons in the most common sporadic form of ALS is still 
largely unexplained. The etiology is likely to be multifactorial and, in particular, to 
involve gene-environment interactions. For this reason, the identification of genes that 
predispose to the development of ALS could help to understand possible toxic events 
that may lead to the loss of motor neurons. Conversely, studies of the mechanisms of 
action of environmental factors might help to identify specific genes that modulate 
neurodegenerative processes. 
The same holds for the other two major neurodegenerative disorders dementia and 
parkinsonism, which generally occur late in life. The identified genetic defects in each 
of these disorders account for only a small proportion of all cases. The etiology for 
the majority of sporadic cases probably involves multiple genes, which are common 
in the general population but have a relatively weak effect on their own, and are likely 
to interact with each other and with non-genetic factors to modulate susceptibility to 
neurodegeneration.
During the last three decades a considerable increase has been observed of 
neurodegenerative disorders like ALS, dementia and parkinsonism. This is paradoxical, 
because populations have overall become healthier and thus more individuals are living to 
the ages at which these diseases are clinically expressed.
Taken together, further clues about genetic susceptibility and environmental triggers for 
neurodegeneration are urgently needed and may have far- reaching implications, including 
the development of preventive strategies and policies that could identify individuals at risk 
and limit exposure to harmful agents.
In this thesis we have followed the leads provided initially by the observations on the 
pacific island Guam and occasional case reports from elsewhere of familial co-occurrence 
of ALS with dementia and parkinsonism. 
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Using an epidemiologic approach we have tested the hypothesis that in some families 
these three disorders occur more frequently than expected by chance. Apparently, in these 
families the genetic susceptibility to neurodegeneration is associated with a broad clinical 
phenotype of ALS, dementia and parkinsonism.
Subsequently, we explored the possibility of associations of putative environmental 
risk factors with ALS, and the possibility of an interactive effect with a family history 
suggestive for a genetic susceptibility to neurodegeneration i.e. a family history of ALS, 
dementia or parkinsonism.  
In this chapter we will discuss methodologic issues concerning the design of this study 
and the analysis of the data. Furthermore, we discuss the main findings in the light of 
the current knowledge and ongoing research in the field of adult onset neurodegenerative 
disorders. We end with our expectations for future research and practical suggestions for 
attending patients with a genetic susceptibility to the late-onset neurodegenerative disorder 
ALS. 
Methology
Two elements, the validity and the precision of the study design, will be discussed here.
Validity 
Selection bias 
We avoided ascertainment or selection bias by describing our study objectives very 
generally when inviting subjects to participate. This should have reduced the possibility 
of selective participation of ALS with specific antecedent medical conditions or other 
presumed risk factors.
The Neurological Institute of Columbia Univeristy Medical Center is known for an interest 
in the research for ALS. For that reason we cannot exclude that patients who were better 
informed about this were more likely to be referred. Because the Neurologic Institute was 
not known for research on specific environmental exposures, is seems unlikely that this 
Institute may have attracted disproportionately more ALS patients with specific exposures, 
such as those who lived in Guam.
The participation rate was 96% for ALS patients and 89% for controls. This argues against 
strong selection related to non-participation.
The validity of the data also depends on the recall of the requested information and on 
the willingness of the participant to share this information. To diminish the possibility 
of information bias, we selected controls that were hospitalized or seen as outpatients for 
severe neurologic conditions, because we expected that the severity of their disorder might 
have evoked a level of concern comparable to that of the ALS patients about the possible 
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causes of their neurologic problems. Nevertheless, since ALS is more severe than most 
of the diseases in the controls, some recall bias cannot be excluded. The diagnoses of the 
controls included stroke (23%), radiculopathy or spinal cord compression (36%), peripheral 
(sensory or motor) neuropathy (23%), multiple sclerosis (4%), and myopathy (9%);in the 
remaining 5%, no neurological abnormality was detected. 
The selection of controls should have minimized the differences between patients and 
controls in recall of antecedent events and reduce ‘family information bias’ (ie, more 
complete recall of the family history by ALS patients than by controls).
For family history data the ascertainment of information on relatives depends on the 
knowledge of the participant regarding the health status of relatives. The validity of the 
information will thus not be equally reliable for all relatives.  To determine the validity 
of the family data, when possible, medical record of relatives should be reviewed. Some 
investigators choose to interview more than one relative, to enhance the validity of the 
family data. 
Generally, the sources of misclassification are difficult to avoid in these types of studies, 
especially when the research concerns fatal adult onset disorders, for whom most affected 
relatives are deceased. Underreporting and under-evaluation are bigger concerns than 
overreporting in family history studies. The validity of family history data is expected 
to be inversely associated with distance in relationship, generally resulting in more 
underreporting and under-evaluation of second-degree than in first-degree relatives. 2
To reduce reporting bias of the family history we used a very structured approach to obtain 
the family histories. Our family history questionnaire consisted of 30 questions about 
the family composition and an additional 17 questions for each relative separately (see 
Appendix).
We also evaluated the possibility of differential recall of the family history by comparing 
ALS patients and controls in terms of the proportion of their relatives reported to have 
conditions that were unlikely to be associated with ALS.
To reduce information bias further we use a very structured approach to obtain information 
on the exposures. The association of specific exposures with ALS depends on the method 
of exposure assessment. We attempted to reduce information bias of occupational histories 
by using job titles and job descriptions to characterize occupations at increased risk for 
specific exposures. However these procedures cannot prevent potential misclassification 
of true exposure. In absence of direct measurements of exposure self- reported exposure 
information may lead to misclassification bias. However, we found it reassuring that 
cases and controls did not differ in self-reported exposure to lead or aluminum, two 
exposures whose possible relation to ALS has been widely publicized. This provides some 
some assurance that overreporting by cases was not a major source of bias in exposure 
assessments.
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Confounding
The study was designed to control for the possible confounding effects of age, gender and 
socioeconomic status. In the analysis we have further controlled for confounding by the use 
of a logistic conditional regression model. 
Precision
The precision of the study depends on its statistical power and thereby on the sample size. 
In this study the precision was qualified with 95% confidence intervals. 
Although this was one of the largest case-control studies of ALS, our sample size was 
limited. As a general rule we had sufficient sample size for the analysis of individual 
determinants (perhaps not for some of the determinants that were less frequent, i.e 
parkinsonism). The sample size was not sufficient to study the interaction of individual 
determinants with a family history of ALS, dementia or parksinonism, i.e. to study gene-
environment interaction.
Genetic associations between amyotrophic lateral sclerosis,   
 dementia and parkinsonism
Many neurodegenerative disorders, including ALS, Parkinson’s disease, Alzheimer’s 
disease, frontotemporal and Lewy body dementia are characterized by neuronal damage 
that may be caused by toxic or structurally abnormal, aggregation–prone proteins. These 
disorders are clinically separate disorders, yet they seem to share common neuropathologic 
features, which eventually may cause overlapping clinical symptoms. 3
They are all characterized by the accumulation of proteinaceous inclusions in neuronal 
cells and the loss of neurons. When misfolded proteins, including tau, beta amyloid, 
or α-synuclein accumulate in sufficient quantity, they are prone to aggregation. 
Insoluble aggregates of disease-related proteins may be deposited in microscopically 
visible inclusions or plaques, the characteristics of which are often disease specific. 
These include ubiquitin positive intracellular inclusions in ALS and in some forms of 
frontotemporal dementia, tau containing intracellular neurofibrillar tangles in other forms 
of frontotemporal dementia and in Guamanian ALS, beta-amyloid containing extracellular 
plaques and tau containing intracellular neurofibrillary tangles in Alzheimer’s disease, 
α-synuclein containing Lewy bodies in parkinsonims and Lewy Body dementia, and the 
intranuclair ubiquitin positive inclusions in Kennedy’s disease (spino-bulbar muscular 
atrophy). 4 5, 6
The explanation for the formation of the pathological hallmarks of the disease and the 
selective vulnerability of specific groups of neurons to cell death is difficult. Different 
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regions of the brain may significantly vary in susceptibility to specific genetic defects, in 
expression of specific proteins and in interactions with environmental factors.
The recent cloning and subsequent functional analysis of several genes involved has begun 
to reveal the molecular pathogenesis of some of these disorders, and will eventually yield 
an answer for the controversial issue whether inclusion bodies are pathogenic, incidental or 
a beneficial coping response of the affected cells. 7 
Clearly, the genetic classification of disorders bearing overlapping features of ALS, 
dementia and parkinsonism will also be helpful in gaining insight in the pathways leading 
to neurodegeneration.
The number of genes implicated in the pathogenesis of ALS is constantly increasing, and 
now also includes genetic defects that are predominantly associated with clinical signs 
of only upper or only lower motor signs.  Since motor neurons are amongst the longest 
cells in the body they require highly specialized adaptations for protein trafficking. 
Genetic vulnerability to defects in the processing or the axonal transport of proteins was 
identified in a number of genetic diseases of the motor neurons with overlapping features 
of ALS, hereditary spastic paraparesis, spinal muscular atrophies or peripheral motor 
neuronopathies. 8 9 10 11 12 13 14 15Several highly penetrant genes have been identified for 
rare mendelian inherited forms of the major neurodegenerative disorders, including some 
disorders with overlapping features (see table).
The identification of genes increasing susceptibility to neurodegeneration, which are more 
and more associated with the majority of sporadic forms of ALS, dementia or parkinsonism 
is very difficult. The same is true for the estimation of the magnitude of their effect and 
their relationship to environmental exposures, principally for two reasons. 
First, neurodegeneration is a heterogeneous concept, perhaps more so than any other 
multifactorial condition. Neurodegeneration occurs in various clinical syndromes with 
a varying decline of cognitive, motor and coordination skills of the neural system. Thus 
the exact delineation of the clinical phenotype, historically regarded as a fundamental 
prerequisite for any genetic analysis, can be clinically difficult. 
Second, neurodegeneration is most often age-related and a rarely has sufficient affected 
relatives for genetic analysis let alone a large pedigree.
This picture has led investigators to change from classic linkage analysis to alternative 
strategies, usually association studies with polymorphisms in candidate genes and 
comparison of their frequencies between unrelated cases and controls.
Greater success has been achieved with the mendelian inherited conditions of ALS, 
dementia, and parkinsonism. Although these studies have helped our understanding of the 
pathophysiology, their public health implications have as yet remained limited.
We find ourselves in a curious position, because we are searching for one gene or a few 
that play a major role in at least three distinct pathological processes. Perhaps the answer 
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lies with a more fundamental understanding of polygenic disorders. We are dealing with 
probabilities not certainties. Carriage of an at risk haplotype does not guarantee disease. 
Maybe genetic predisposition to a neurodegenerative disease ought to be seen in terms of 
molecular processes rather than of specific clinical diagnoses. Identifying a susceptibility 
gene for a clinical syndrome should not be so dogmatically compartimentalised but must be 
interpreted in view of the pathophysiology.
The work presented in this thesis seems to support this view.
Using a genetic epidemiologic strategy we found evidence for a shared genetic 
susceptibility for degeneration of the motor system (ALS), the cortical areas with cognitive 
functions (dementia) and the subcortical nuclei involved in motor control (parkinsonism).
In the families where we observed familial co-occurrence of ALS, dementia or 
parkinsonism, these diseases occurred randomly. This variability within families with 
ALS in age at onset, the rate of progression and the occurrence of extrapyramidal features 
is now well recognized. 4, 16-19 The phenotypic variability suggests that the selective 
vulnerability of specific groups of neurons to the formation of pathological hallmarks 
or cell death depends on a complex variation within different regions of the brain in the 
expression and interaction of genes as well as in the interactions with environmental 
factors.
Gender maybe one of the factors that influence the expression of disease.
All epidemiologic surveys of ALS report consistently a male preponderance. Although 
the extend of the excess of ALS in men varies across studies, the male preponderance is 
on average at least 1.5 to 1, and concerns all forms of sporadic ALS, both the Western 
type of ALS as the Guamanian ALS-PDC. Efforts to explain the male preponderance 
have addressed issues such as gender related job exposure to environmental risk factors 
(for example weldering, using a jackhammer, or being exposed to pesticides, solvents 
or electrical shock) and misdiagnosis of X-linked bulbar dystrophy (SMBA, Kennedy’s 
disease). 
Alternatively, evidence for protective influences in women is accumulating from 
observations in familial ALS. Specifically in the L126S, L84V and the A4T in the SOD1-
gene mutations non-penetrance or reduced penetrance in female relatives has been 
observed. The L126S mutation of SOD-1 presented with extremely mild symptoms in the 
legs in male patients and non-penetrance at age 80 in female carriers.20 The L84V mutation 
showed rapid progression in males while the female patients began to be affected about 20 
years later than the male patients. 21 
An other missense mutation of the SOD1 gene, A4T, showed rapid progression in affected 
males and non-penetrance in the mother of the patient, who carried the same mutation. 22
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Estrogens are supposed to have a role as free radical scavengers 23 or anti-apoptotic agents 
24, 25 and these functions may compete with the neurotoxic activity of mutant SOD-1 
protein. It remains to be elucidated how these neuroprotective effects sustain neuronal 
survival even after menopause.
In one case control study menarche occurred later and menopause earlier in women 
affected with ALS, implicating a relatively short reproductive period. This inverse 
association supports the hypothesized protective effect of estrogens in the etiology of ALS. 26
Several lines of evidence from human and animal studies suggest a protective role for 
estrogens in the predisposition to parkinsonism and dementia. 27 28 The prevalence of 
parkinsonism is higher in men than in women by an approximately 3:2 ratio. 29 
While the exact mechanisms by which estrogen exerts its effect are still unclear, there is 
increasing evidence that estrogens may bind to intracellular receptors that enter the nucleus 
and act as transcription factors to regulate gene expression in the striatum. Estrogens may 
also act via nongenomic mechanisms such as membrane receptors, interaction with striatal 
dopamine receptors, and regulation of ion channels, protect against β-amyloid toxicity or 
excitoxicity. 27, 30, 31
To date, the findings about efficacy of estrogens therapy in preventing cognitive decline 
and dementia in postmenopausal women are mixed. Some case-control studies, cross-
sectional studies, and prospective studies have reported an association between lower risk 
for dementia and postmenopausal estrogen supplementation. Meta-analyses of the potential 
protective effect of estrogen against dementia have reported risk reductions. Clinical trials 
of estrogen therapy did not confirm a protective effect for dementia nor did women with 
Alzheimer’s disease benefit on cognitive performance. 32 
In men, testosterone concentrations diminish with age, which suggests a link between 
testosterone depletion and the frequency of ageing-related neurodegenerative disorders. 
33-35 The mechanisms by which testosterone could improve cognition and prevent cognitive 
impairment include modulation of neurotransmitters, stimulation of neuronal connectivity, 
decreased β-amyloid peptide production, and prevention of excitotoxicity. Alternatively the 
conversion of testosterone to oestradiol (via aromatase) might influence cognition. 
Androgen receptors that bind testosterone co-localize in the brain with estrogen receptors 
and are found mainly in regions involved in learning and memory, such as the thalamus, 
hippocampus, and the deep layers of the cerebral cortex. 36 The X-linked, androgen 
receptor (AR) gene associated with spino- bulbar muscular atrophy (Kennedy’s disease) 
bears resemblance in clinical features with ALS. The AR gene contains a CAG repeat 
expansion within exon 1 that codes for a polyglutamine sequence of variable length. 37 
Lengths of the CAG repeat appears to be inversely correlated with transcriptional activity, 
and long CAG repeats in the AR gene has been associated with androgen insensitivity.  38 
These results suggest that the greater the impairment of AR function, the higher the risk for 
cognitive decline in elderly men. 39
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Neurodegenerative disorders such as ALS, diseases, Alzheimer’s disease, frontotemporal 
dementia (FTD) and parkinsonism are increasingly being realized to have common 
cellular and molecular mechanisms including the toxic effect of misfolded protein, protein 
aggregation and inclusion body formation. 40 41 These neurodegenerative diseases exhibit 
loss of nerve function in different ways, from memory lapses to uncontrollable muscular 
movements, but it is now believed that these diseases share many common molecular 
mechanisms. 
The question is to find which mechanisms initiate the neurodegenerative process and to 
discover if aggregation is the cause or the effect of the diseased neuron. Although, the 
conspicuous nature of large aggregates in affected tissue makes them attractive candidates 
for causing disease, whether these aggregates are integrally involved in the disease process 
or are beneficial in sequestering toxic by-products is unknown. 42
Initially misfolding of the protein can induce novel toxic properties and/or prevent normal 
protein functioning. There is evidence that in these diseases, disease-causing proteins 
severely interferes with the working of the ubiquitin-proteasome system (UPS), the cellular 
machine responsible for eliminating damaged proteins within the cell. 43 40, 44 Another 
possibility is that misfolded or damaged proteins, common to all human neurodegenerative 
diseases, may clump together to form aggregates. The protein aggregates, bind to the UPS 
machine irreversibly and prevent the complete degradation of the proteins, explaining the 
disease process. 45
The ubiquitin-proteasome system is responsible for cell homeostasis. In healthy cells, 
proteins perform their function and then, with the help of the proteasome, disappear. If 
idle and damaged proteins remain, their presence can affect cell behavior. Once bound, the 
toxic proteins do not release the proteasome. This interference with the normal clearance 
of proteins has a cumulative and amplifying negative effect. The proteins that are normally 
degraded build up. The toxic proteins and proteasome are bound together in a close and 
stable fashion, indicating that the proteins are trapped within the proteasome. This could 
explain the negative consequences on the health of the cell in which disease builds over 
decades before symptoms result. 
Conversely, it has been suggested that failure to identify, detect abnormal and misfolded 
protein and transport them for degradation to the UPS system, causes aggregation. 
When proteins accumulate in sufficient quantity, they are prone to aggregation. Insoluble 
aggregates of disease-related proteins may be deposited in microscopically visible 
inclusions and plaques, the characteristics which are often disease specific. 46 47
Most of our knowledge of UPS dysfunction has come from identification of genes linked 
to familial forms of parkinsonism. Two of these genes, Parkin (PARK2) and UCHL1 
(PARK5), are functional in the ubiquityl ligase pathway. The normal function of these 
ligases is to recognize target proteins for degradation, or transport to other part of the cell. 
48-50  
GENERAL DISCUSSION
123
Mutated, Parkin and UCHL1 reduce the normal ability to degrade protein and decrease net 
UPS activity. 51, 52
Pathogenic mechanisms in Alzheimer’s disease are strongly related to the destabilisation 
of the structure of β amyloid, resulting in formation of insoluble, disease causing protein 
aggregates in the brain. 47 The concept that monomeric aberrant proteins are the initiating 
event pertains also to α-synuclein in parkinonism. In the tauopathies, the pathogenic effects 
of aberrant tau includes the inhibition of the UPS by the soluble protein and the potentially 
toxic effect of large aggregates of hyperphophorylated and misfolded tau as paired helical 
filaments, leading to neurofibrillary tangles. 46
Novel toxic properties of misfolded proteins may also affect mitochondrial functioning. 
A major cause of ALS is a mutation in the ubiquitous expressed SOD-1 gene, but 
the mechanisms for toxicity to motor neurons is unknown. Multiple disease causing 
mutants, not wild type SOD-1, are now demonstrated to be recruited to mitochondria, 
only in affected tissue. 53 Highly preferential association with spinal cord mitochondria 
is seen in human ALS for a mutant SOD1 that accumulates only to trace cytoplasmic 
levels, suggesting that damage from action of spinal cord-specific factors that recruit 
mutant SOD1 to spinal mitochondria as the basis for their selective toxicity in ALS. 54, 55 
Mitochondrial localization of parkin, PINK1 and DJ-1, the proteins of respectively PARK2, 
PARK6 and PARK7, also suggest a role in mitochondrial dysfunction in parkinsonism. 5
Interestingly, the most common cause of the axonal type of peripheral neuropathy, CMT2, 
involves mutations of the MFN2 gene, a mitochondrial GTPase. 56
Oxidative stress is another neurotoxic mechanism involved in the UPS inhibition. Further 
evidence for the involvement of oxidative stress in neurodegeneration is presented by the 
association of ALS with changes in the hypoxia induced expression of vascular endothial 
growth factor VEGF. 57 These data confirm that chronic vascular insufficiency plays an 
important role in the degeneration of motor neurons. In parkinsonism oxidative stress has a 
role in the pathogenic process, as the protective function against oxidative stress. 58 
The initiating events in the neurodegenerative processes briefly described here involve 
genetic defects and may involve additional interaction with environmentally induced 
toxicity in the more common sporadic forms of disease.
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Table. Major genes for amyotrophic lateral sclerosis and associated dementia and parkinsonism
Disease Genes Locus Inheritance Main clinical features Suggested  molecular mechanism Neuropathology Ref.
ALS1 SOD1 21q22
AD
AR
adult onset, short survival
adult onset, slowly progressive
toxic gain of function; proteasomal inhibition, 
aggregate formation; oxidative stress; axonal 
transport impairment; mitochondrial dysfunction
ubiquitin containing cytoplasmatic and 
axonal inclusions 
84-86
ALS2 Alsin 2q33-34 AR
juvenile ALS or PLS, infantile ascending HSP with 
progressive spasticity of limb and facial muscles, 
bulbar or pseudobulbar symptoms, distal muscular 
weakness and atrophy
premature truncated alsin is rapidly degradated, 
impairing endosomal trafficking
87-92
ALS3 18q21 AD Adult onet 93 
ALS4 Senataxin 9q34 AD
slowly progressive, distal spinal muscular atrophy 
with normal life expectancy with and without 
pyramidal signs; spastic paraplegia with amyotrophy 
(Silver syndrome); absence of bulbar involvement
dysfunction of helicase activity,
impairing mRNA processing
13, 15, 94
ALS5 15q12-21 AR 950
ALS6 16q12.1-2 AD
adult onset ALS; ALS/FTD
survival 3-20 years , reduced penetrance
96-98
ALS7 20p13 AD 98
ALS 8 VAPB 20q13 AD
intrafamilial varability of adult onset slowly 
progressive SMA, adult onset slowly progressive 
ALS with tremor and long survival, rapidly 
progressive ALS
impairment of intracellular membrane trafficking 83
ALS/FTD 9q21-22 AD ALS-dementia/FTD
ubiquitin containing inclusions without 
tauopathy 99
ALS/FTD
t(18;21)
(q23;q22.1)
AD ALS-FTD 100 
FTDP-17 Tau 17q21 AD FTD-parkinsonisme-amyotrophy assembly of microtubules tauopathy 101, 102
Guam
ALS/PDC
ALS, dementia, parksinonism tauopathy 103, 104
FTDP 17q21-22 AD FTD-parkinsonism tauopathy 105
FTD 3 AD FTD tauopathy 106, 107
PARK8
LRRK2
Dardarin
12p11.2-
q13.1
AD parkinsonism with dementia, amyotrophy or both
pure nigral degeneration with or without 
neurofibrillary tangles, brainstem Lewy 
bodies, or widespread brainstem and 
cortical Lewy bodies
108-112
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Table. Major genes for amyotrophic lateral sclerosis and associated dementia and parkinsonism
Disease Genes Locus Inheritance Main clinical features Suggested  molecular mechanism Neuropathology Ref.
ALS1 SOD1 21q22
AD
AR
adult onset, short survival
adult onset, slowly progressive
toxic gain of function; proteasomal inhibition, 
aggregate formation; oxidative stress; axonal 
transport impairment; mitochondrial dysfunction
ubiquitin containing cytoplasmatic and 
axonal inclusions 
84-86
ALS2 Alsin 2q33-34 AR
juvenile ALS or PLS, infantile ascending HSP with 
progressive spasticity of limb and facial muscles, 
bulbar or pseudobulbar symptoms, distal muscular 
weakness and atrophy
premature truncated alsin is rapidly degradated, 
impairing endosomal trafficking
87-92
ALS3 18q21 AD Adult onet 93 
ALS4 Senataxin 9q34 AD
slowly progressive, distal spinal muscular atrophy 
with normal life expectancy with and without 
pyramidal signs; spastic paraplegia with amyotrophy 
(Silver syndrome); absence of bulbar involvement
dysfunction of helicase activity,
impairing mRNA processing
13, 15, 94
ALS5 15q12-21 AR 950
ALS6 16q12.1-2 AD
adult onset ALS; ALS/FTD
survival 3-20 years , reduced penetrance
96-98
ALS7 20p13 AD 98
ALS 8 VAPB 20q13 AD
intrafamilial varability of adult onset slowly 
progressive SMA, adult onset slowly progressive 
ALS with tremor and long survival, rapidly 
progressive ALS
impairment of intracellular membrane trafficking 83
ALS/FTD 9q21-22 AD ALS-dementia/FTD
ubiquitin containing inclusions without 
tauopathy 99
ALS/FTD
t(18;21)
(q23;q22.1)
AD ALS-FTD 100 
FTDP-17 Tau 17q21 AD FTD-parkinsonisme-amyotrophy assembly of microtubules tauopathy 101, 102
Guam
ALS/PDC
ALS, dementia, parksinonism tauopathy 103, 104
FTDP 17q21-22 AD FTD-parkinsonism tauopathy 105
FTD 3 AD FTD tauopathy 106, 107
PARK8
LRRK2
Dardarin
12p11.2-
q13.1
AD parkinsonism with dementia, amyotrophy or both
pure nigral degeneration with or without 
neurofibrillary tangles, brainstem Lewy 
bodies, or widespread brainstem and 
cortical Lewy bodies
108-112
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Environmental risk factors for amyotrophic lateral
sclerosis
During the past decade, genetic approaches to the study of ALS have been paralleled only 
partly by an increase in our understanding of the role of environmental risk factors and the 
mechanisms of gene-environment interaction. 
The finding that initiated the intensive search for environmental toxins in 
neurodegenerative disorders was the discovery in the late 1970’s that the drug containing 
l-methyl-4phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) induces in intravenous drug 
users neurological features resembling Parkinson’s disease. 59 This observation could be 
reproduced in various animal models.
Also investigators have been trying to identify the etiologic trigger of a prototypical 
neurological disorder found in the Chamorro people in the western Pacific, with features 
of ALS, parkinsonism and Alzheimer-like dementia (ALS/PDC) 60. Viral agents have been 
virtually been ruled out 61 and the disease incidence obviously declined in all three affected 
western Pacific areas. Since then the search for the etiology of this disorder has focused on 
genetic susceptibility and non-transmissible environmental factors that are vanishing as the 
susceptible population adapts to a modern lifestyle.
Epidemiologic studies made the link between preference for Chamorro food and the high 
incidence of Guamanian ALS/PDC. 62 Data were consistent with the hypothesis that the 
seeds of the neurotoxic cycad palm, a traditional but declining source of food for the 
Chamorro, plays a role in the etiology of western Pacific ALS/PDC. The cycad seeds were 
either processed traditionally in cycad flour or ingested indirectly by the consumption of 
indigenous flying foxes. These foxes were foraging on the cycad seeds and are supposed 
to contain high concentrations of the neurotoxic components of the seeds. 63 64 The cycad 
hypothesis has been strengthened by recent studies that demonstrate a direct correlation 
between the presence of ALS/PDC in populations and the exposure to the toxin.
The results of this study bolster the vision that exposure to slow acting toxic agents 
are important in the pathogenesis of ALS, most likely in combination with a genetic 
predisposition. In studies described in this thesis we found that for citizens of the United 
States even a short stay on Guam during the time of endemic ALS was associated many 
years later (mean 43 years, range 27-57) with an increased risk for ALS. 
The study of environmental risk factors for age-related diseases as ALS is difficult for 
several reasons. Important environmental exposure and gene-environment interactions may 
occur well before the onset of clinical manifestations and remain undetected years later.
Moreover, the severe neurodegenerative changes that underlie the symptoms of ALS may 
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be the result of additive or synergistic effects of multiple exposures and, over the years, 
these effects could be compounded by increased vulnerability of the ageing motor neuron 
system to toxic injury. Hence, repeated insults, chemical interaction, age-related effects and 
genetic susceptibility should also be considered when investigating the role of neurotoxins 
in the pathogenesis of ALS.
The results of our study on environmental effects (chapter 5.3) suggests an association 
between ALS and exposure to pesticides, a history of tuberculosis and short residence on 
Guam.
Pesticides are a broad range of substances most commonly used to control insects, weeds, 
and fungi (plant diseases). They are frequently classified by target organism or mode of use 
as insecticides, herbicides, fungicides, or fumigants. Individuals are frequently exposed 
to many different pesticides or mixtures of pesticides, either simultaneously or serially, 
making it difficult to identify effects of particular agents. Poisoning by acute high-level 
exposure to pesticides has well-known neurotoxic effects, but whether chronic exposure 
to moderate levels of pesticides is also neurotoxic is more controversial. It is possible that 
the most sensitive manifestation of pesticide neurotoxicity is a general malaise lacking in 
specificity and related to mild cognitive dysfunction, similar to that described for Gulf War 
syndrome. 65
Pesticide exposure may also be associated with increased risk of neurodegenerative 
disease, particularly Parkinson’s disease. 66 67
The association with pesticides, agricultural chemicals or insecticides and ALS was 
investigated in several studies, some of which show a modest association with ALS. 68 69 70 
71 72 In addition, a cohort study found an increase of ALS in workers in a chemical industry 
involving exposure to pesticides. 73, 74 
We also found that ALS was associated with a history of tuberculosis. To our knowledge 
this association has not been reported before and we cannot rule out that this observation 
was due to chance. The outcome of some studies suggested that ALS is associated with 
an increased milk ingestion, especially in the youth, which might be linked with bovine 
tuberculosis infections. 69, 75  However, in our study we did not find a link between a 
history of tuberculosis and living on a dairy or cattle farm. Neither was ALS associated 
with neurologic sequelae of meningitis tuberculosa or spinal tuberculosis in our study. 
Several explanations could be considered for the association with tuberculosis: a long-term 
neurotoxic effect of a tuberculosis infection or, a neurotoxic effect of the antibacterial 
medication, a tuberculosis infection mediated immune respons involving antibodies against 
motorneurons, or a common (immunologic) increased susceptibility for tuberculosis and 
ALS. 76
Further stratification of the analysis of environmental risk factors did not show interactions 
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with a family history of ALS, dementia and parkinsonism, probably because the statistical 
power was not sufficient with the available sample size.
Suggestions for genetic counselling
In bioethical considerations about illnesses such as ALS there is increased recognition that 
the patient and family must be allowed to share crucial decision making. This refers both 
to questions regarding treatment as to genetic issues. However, the genetic counselling of 
incurable neurodegenerative disorders is not a straightforward matter and requests to be 
tailored to the needs and the psychological makeup of the patient and his family. 77, 78
The severity of the disorder is likely to evoke concern about possible causes and about risk 
for the family. In our point of view, we (the physicians) owe the patients and their families 
appropriate information on the genetic complexity of the disorder and possible recurrence 
risks. This will help preventing the feeling of to be left with unanswered questions and 
unaccounted issues, especially in cases where the disease is familial. Moreover, the reliable 
assessment of possible genetic risks, will allow reassurance in the majority of cases. 
Essentially, following the model of genetic testing for Huntington’s disease, consensus 
guidelines for ALS genetic counselling and testing should be developed. 79, 80
In view of the accumulating evidence for complex genetic causes in ALS, we urge to 
ascertain the family history of neurodegenerative disorders in all patients. 
The phenotypic variability of the major ALS genes shows that clinical diagnosis of 
distal spinal muscular atrophy (dSMA type V), distal Charcot Marie Tooth disease 
type 2D (dCMT2D), primary lateral sclerosis and spastic paraplegia can belong to the 
broad spectrum of familial ALS. Therefore we propose that ascertainment of the family 
history of ALS patients include questions about diagnosed ALS, distal spinal muscular 
atrophy, spasticity, Alzheimers’s disease, Pick’s disease or frontotemporal dementia, or 
any other kind of dementia, or parkinsonism in relatives. Probing for the specific features 
(personality changes, extreme suspiciousness, or loss of decorum preceding the onset of 
decline in memory) may help differentiate the frontotemporal type of dementia. Additional 
information about functional ability, signs of parkinsonism (resting tremor, bradykinesia, 
postural instability, rigidity), and use of L-dopa or similar medication may help to identify 
extrapyramidal involvement. Furthermore information should be collected on preexisting 
conditions, causing symptoms of dementia or parkinsonism (intracranial neoplasm, stroke, 
alcoholism). When appropriate a molecular analysis should be performed to confirm the 
clinical diagnosis.
In some instances, we have to consider the psychological burden of a genetic diagnosis 
for the patient and the family. Based upon the pattern of inheritance in the family the 
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possibility of genetic counselling must be discussed with individuals at risk and the 
possible importance for healthy relatives must be mentioned. 80, 81
Furthermore, families should be allowed to have an option to store DNA for future 
genotyping of genetic susceptibility to neurodegeneration. Specific genetic changes leading 
to susceptibilities, might in the future lead to preventive and therapeutic measures. 
The same considerations pertain to the neuropathologic classification of ALS and of the 
relation with dementia and parkinsonism. Discussion of these issues might help make 
preliminary arrangements for a post-mortem examination that may simultaneously be 
instrumental for the counselling of the family and for medical research of this complex of 
neurodegenerative diseases. 
In our own experience patients generally welcome the opportunity to share their family 
history and/or participate in this family history study. Most patients hope that their families 
will eventually profit from the family history of neurological disorders.
Suggestions for future research
The approach of studying potential familial aggregation through self-reported family 
history is useful as a starting point. The results of this thesis illustrate that the application 
of epidemiologic methods might be helpful to test a hypothesis of a shared genetic 
susceptibility. The follow-up is likely to be of a molecular genetic approach.
The recent identification of gene mutations responsible for mendelian inherited ALS and 
susceptibility genes in sporadic cases gives new opportunities to study the interaction 
between the expression of a predisposing gene and exposure to specific neurotoxic 
chemicals. The effect of selected chemicals can be compared in clonal cell lines, primary 
cultered neurones and transgenic animals expressing normal endogenous levels of normal 
protein, overexpressing normal protein and expressing mutant protein. The selective 
vulnerability of individual populations of neurons must be considered. This approach will 
offer an opportunity to study gene-gene and gene-environment interaction and help to 
figure out which environments turn up a gene and which turn it down, which environments 
interact with which proteins and which environments interfere in normal processing 
and functioning of which proteins. 82 83 This hopefully will lead to understanding of the 
pathogenic mechanisms that cause neurodegeneration and to develop effective means for 
cure and prevention. 
Overall rates of the related neurodegenerative disorders, ALS, dementia and parkinsonism 
are much the same in developed countries, and the incidence rises exponentially until 
the eight decade of life. Advances in medical technology have prolonged survival up to 
high ages which has led to a rapid increase in the proportion of patients. The causes of 
the disorders are complex. Workers in epidemiology will have to develop risk models in 
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parallel with changing knowledge of biological risk factors. 
Many promising research avenues are yet to be explored: properly powered genetic studies, 
neuroimaging and other biomarker techniques for diagnosis and disease monitoring. 
Improved diagnosis, wider recognition, and the prospect of disease modification make 
future management of neurodegenerative disorders an exciting specialty.
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Summary
This thesis aims to use epidemiologic methods to investigate genetic and environmental 
factors playing a role in ALS. We conducted a case control study between 1989-1991 at 
the Neurological Institute Columbia University Medical Center in New York. The study 
population consisted of 151 newly diagnosed ALS patients and 140 neurologic controls, 
matched for age (+ 5 years), gender (83 pairs of men and 57 pairs of women) and insurance 
status. 
In chapter 2 the current insights in the relation of ALS, dementia and parkinsonism is 
summarized.  
As described in the review (chapter 3) until the 1960s, ALS was considered to be a 
non-hereditary neurologic disease.  In a land-mark report in 1955, Kurland and Mulder 
described 18 families with hereditary ALS from a 100-year review of the world literature. 
Only in the past decade, genetic analysis of familial forms of ALS led to the identification 
of several mendelian inherited forms of ALS. These familial forms comprise 5-10% of all 
cases. Thus far six autosomal dominant and three autosomal recessive forms were found 
to be associated with familial ALS. In addition, a growing number of genetic defects are 
being associated with syndromes featuring familial recurrence of ALS, frontotemporal 
dementia and parkinsonism. In the 90% of cases were ALS is sporadic, changes in various 
genes have been linked to an increased risk for ALS, so called susceptibility genes. 
Susceptibility genes are thought to interact with other low penetrant genes and/or with 
environmental risk factors.
In chapter 4 of this thesis we used epidemiologic methods to find evidence for a shared 
genetic susceptibility for ALS, dementia and parkinsonism. To do so, we investigated 
familial aggregation of these three disorders in families of ALS patients. In the case-
control study we compared the family histories of ALS patients and controls. A semi-
structured questionnaire was used to ascertain valid information on neurologic conditions 
for each sibling, parent and grandparent, individually. 
The data showed familial recurrence of ALS in five percent of the patients and not in 
controls. We found that the risk (cumulative incidence) of dementia was twofold increased 
for relatives of ALS patients. This association between ALS and dementia was apparent in 
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familial as well as in sporadic ALS. A similar association between ALS and parkinsonism 
was detected. We found that the association between ALS and dementia was stronger in 
first- degree relatives (parents and siblings) than in second- degree relatives (grandparents). 
These findings endorse a genetic effect in familial aggregation of ALS and dementia. 
We then evaluated the associations between dementia and parkinsonism within and 
between the families of ALS patients and controls. In families of ALS patients the risk for 
parkinsonism was significantly higher when dementia occurred in the family than if there 
were no known relatives with dementia. Co-occurrence of dementia and parkinsonism was 
observed twice more frequently in families of sporadic ALS, compared to controls. 
The results of this study show a familial association between ALS, dementia and 
parkinsonism. This suggests shared genetic susceptibilities for the neurodegenerative 
features in the families where these disorders co-occur.  An important observation is, that 
the supposed genetic susceptibility to neurodegeneration also occurs in sporadic ALS. 
 
In chapter 5 we describe that between 1940 and 1965 an unusually high incidence of 
amyotrophic lateral sclerosis (ALS), with co-occurrence in patients and families of a 
parkinsonism-dementia complex (PDC), was observed in the Chamorro population of 
the pacific island of Guam. So far, no genetic causes for ALS/PDC have been found. The 
increased risk of ALS in migrants to and from Guam suggests a combined effect of an 
environmental exposure and a genetic susceptibility. The declining incidence of ALS on 
Guam has been attributed to changes in the consuming patterns of food containing the 
seed of the locally growing cycad palms. These seeds were either processed traditionally 
in cycad flour or ingested indirectly by the consumption of indigenous flying foxes. These 
foxes were foraging on the cycad seeds and are supposed to contain high concentrations of 
the neurotoxic components of the seeds. 
In the second part of chapter 5 we have examined if residence on Guam during the period 
of endemic ALS, contributed to the risk for ALS in citizens returned to the United States. 
We have compared places, dates and the duration of residence outside the continental 
United States for more than one month. We found that a short stay (2-15 months) on 
Guam is associated with ALS in citizens of the United States.  The link between ALS and 
temporary stay in Guam remained even after accounting for other putative risk factors 
such as age, gender, education, traumas, exposure to pesticides, history of tuberculosis 
and family history of ALS, dementia or parkinsonism, and military service. Despite the 
small sample size of this study we detected an association where two larger studies did not. 
The follow-up period in the two earlier studies was shorter, 16-25 years and 15-27 years, 
respectively, than in the present study (43 years, range 27-57). This might indicate that one 
of the key characteristics following the exposure during the period of endemic ALS on the 
pacific island of Guam is the long delay in clinical expression. The toxic exogenous factor 
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in ALS pathogenesis seems to act after quite a short exposition (maybe on genetically 
susceptible people) during the period of endemic ALS on Guam and has a long delay in 
clinical expression. 
In the third part of chapter 5 we further aimed to identify environmental factors which 
may act against a background of increased genetic susceptibility. In the case control 
study described before we investigated putative environmental risk factors for ALS and 
analyzed the interactive effect of each of these proposed risks with a family history of 
ALS, dementia or parkinsonism, which we used as a marker for a genetic susceptibility 
to neurodegeneration. We collected information on antecedent medical histories (specific 
infectious diseases, diabetes, autoimmune disorders, surgery and injuries), exposure 
to animals or to specific environmental toxins (pesticides, aluminum, lead and others), 
occupational histories, smoking habits and the consumption of alcoholic beverages. 
In multivariable analysis, the association with exposure to pesticides and a history of 
tuberculosis remained. 
The epidemiologic analysis of gene-environment interaction in ALS indicates that 
studies with larger sample sizes are needed to allow further stratification for interactions 
between infrequent exposures and the large number of rare genetic susceptibilities to 
neurodegeneration in sporadic forms of ALS. 
This thesis illustrates that a genetic predisposition to ALS might be considered in terms 
of susceptibility to neurodegenerative disease rather than of specific clinical diagnosis. 
Consequently, patients and their families should be given genetic counselling, tailored 
to specific circumstances. When appropriate a molecular genetic analysis should be 
performed to confirm and specify the clinical diagnosis. Also, patients should be offered 
the option to store DNA for future genotyping of susceptibility to neurodegeneration. 
Relatives might profit from future preventive or therapeutic measures for specific genetic 
changes leading to susceptibility for neurodegeneration.
Clearly, the genetic classification of disorders bearing overlapping features of ALS, 
dementia and parkinsonism will be helpful in gaining insight in the molecular pathways 
leading to neurodegeneration. The identification of gene mutations responsible for familial 
aggregation of ALS, dementia and parkinsonism will open new opportunities to understand 
at the molecular level the influence of predisposing genes and the exposure to specific 
environmental factors. This interaction might explain the selective vulnerability of specific 
groups of neurons to the pathologic hallmark of disease and cell death.

141
CHAPTER 7
Samenvatting
Het doel van dit proefschrift was met epidemiologische onderzoeks methoden een 
gezamelijke  genetische predispositie voor amyotrofische lateraal sclerose (ALS), dementie 
en parkinsonisme, en de invloed van omgevingsfactoren te bestuderen. Hiervoor werd 
een patient-controle studie verricht van 1989 to 1991 op het Neurological Institute van het 
Columbia University Medical Center in New York. De onderzoekspopulatie bestond uit 151 
patienten bij wie recent de diagnose ALS was gesteld en 140 controle patienten, met andere 
neurologische aandoeningen, die dezelfde leeftijd (+ 5 jaar) en geslacht hadden als de ALS 
patienten, en die in dezelfde klasse medisch verzekerd waren.
Tot ver in de twintigste eeuw was men zich nauwelijks bewust van de erfelijke vormen van 
amyotrofische lateral sclerose (ALS). Hierin kwam geleidelijk verandering na de publicatie 
van Kurland en Mulder in 1955, waarin zij een overzicht gaven van achtien families met 
ALS, die in de afgelopen 100 jaar in de literatuur werden beschreven. 
In hoofdstuk 2 wordt de huidige kennis over de relatie tussen ALS, dementie en 
parkinsonisme samengevat.
Zoals in het overzichtsartikel (hoofdstuk 3) wordt beschreven heeft de groeiende 
belangstelling voor en onderzoek naar familiaire ALS er inmiddels toe geleid dat nu 
bekend is dat bij ongeveer 5 tot 10 procent van de ALS patienten een erfelijke vorm van de 
ziekte met een mendeliaans overervingspatroon voorkomt. Pas in het afgelopen decennium 
kon met de toepassing van moderne moleculaire onderzoekstechnieken het gen of de 
locatie van verschillende - maar lang nog niet alle- mendeliaans overervende vormen van 
ALS worden geidentificeerd. Inmiddels kennen we zes autosomaal dominant overervende 
en drie autosomaal recessief overervende erfelijke vormen van ALS. Bovendien worden 
in rap tempo steeds meer genen ontdekt, die het voorkomen van combinaties van ALS, 
frontaalkwab dementie en/of  parkinsonisme in families verklaren.
Ook worden, ondanks dat bij het merendeel (90%) van de ALS patienten de ziekte niet 
in de familie voorkomt, nu ook bij sporadische patienten veschillende genmutaties of -
polymorphismen waargenomen. Vermoedelijk bestaat er ook bij  sporadische patienten 
een wisselwerking tussen predispositie genen en schadelijke omgevingsfactoren, die ieder 
opzich onvoldoende penetrant zijn om ALS te veroorzaken.   
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Hoofdstuk 4 van dit proefschrift bevat het epidemiologische onderzoek naar een 
gemeenschappelijke genetische aanleg voor ALS, dementie en parkinsonisme. Hiertoe 
werd onderzocht of deze drie aandoeningen vaker in de families van ALS patienten 
voorkomen dan in families van controle personen. Dit werd onderzocht door de 
familiegeschiedenis van ALS patienten met die van controle personen te vergelijken. Om 
zo betrouwbaar mogelijk informatie te krijgen over neurologische aandoeningen in de 
familie werd van alle deelnemers voor ieder familielid afzonderlijk (broers, zusters, ouders 
en grootouders) een gestructureerde vragenlijst afgenomen. 
Uit deze gegevens bleek dat in vijf procent van de families van de ALS patienten er 
familieleden waren met ALS terwijl in de families van de controles geen ALS voorkwam. 
Ook kon worden vastgesteld dat de familieleden van ALS patienten twee keer meer kans 
(cumulatieve incidentie) hadden op dementie dan de familieleden van de controle personen. 
De associatie tussen ALS en dementie werd zowel waargenomen in familiaire ALS als 
in families van sporadische ALS patienten.  Een soortgelijk verband werd vastgesteld 
tussen ALS en parkinsonisme. De associatie tussen ALS en dementie was duidelijker in 
eerstegraads familieleden (de ouders, broers en zusters) van de ALS patienten dan in hun 
tweedegraads bloedverwanten (grootouders). 
Vervolgens werd onderzocht of er in de families van ALS patienten een verband is tussen 
het voorkomen van dementie en het voorkomen van parkinsonisme. We vonden dat de 
kans op parkinsonisme statistisch significant hoger was in families van ALS patienten 
wanneer bij tenminste één van de familieleden dementie was vastgesteld dan wanneer dit 
niet het geval was. Tevens bleek dat bij sporadische ALS patienten de kans op het samen 
voorkomen van dementie en parkinsonisme in de familie twee keer groter was dan bij 
controle personen.
De resultaten van dit onderzoek bevestigden dientengevolge het vermoeden dat er een 
genetisch verband is tusssen ALS, dementie en parkinsonisme. Het veronderstelde 
familiaire verband tussen ALS, dementie en parkinsonisme zou verklaard kunnen worden 
door een gemeenschappelijke erfelijke aanleg voor neurodegeneratie in de families waarin 
deze drie neurologische aandoeningen voorkomen. Opvallend was dat de veronderstelde 
genetische aanleg voor neurodegeneratie ook in families van de sporadische ALS patienten 
werd waargenomen. 
In Hoofdstuk 5 worden omgevingsfactoren onderzocht. 
In de periode tussen 1940 en 1965 werd een ongewoon hoge incidentie van ALS 
waargenomen in the inheemse Chamorro bevolking van het eiland Guam in de Stille 
Oceaan.  Opmerkelijk was dat bij veel van de Chamorro patienten evenals in hun familie 
een parkinsonisme-dementie complex (PDC) voorkwam. Tot nu toe is de genetische 
oorzaak voor ALS/PDC op Guam nog niet opgehelderd. Wel zijn er recent aanwijzingen 
gevonden voor schadelijke omgevingsfactoren.
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Omdat migranten van en naar Guam een verhoogd risico op ALS hadden werd een 
wisselwerking tussen blootstelling aan schadelijke omgevingsfactor(en) en een erfelijke 
aanleg voor neurodegeneratie verondersteld. De recent waargenomen dalende incidentie 
van ALS op Guam werd toegeschreven aan een verandering in het consumptiepatroon 
van voedsel dat zaden bevat van de inheemse cycade palm. Deze zaden werden hetzij 
op traditionele wijze tot meel verwerkt of indirect genuttigd via het eten van inheemse 
vleermuisjes. Omdat deze dieren zich voedden met de cycade zaden veronderstelde men dat 
zij hoge concentraties bevatten van het neurotoxische bestanddeel van de zaden. Inmiddels 
zijn de betreffende vleermuizen van het eiland verdwenen.
In het eerste deel van  het vijfde hoofdstuk werd onderzocht of een verblijf op Guam 
gedurende de periode waarin ALS endemisch was op het eiland, ook voor inwoners van de 
Verenigde Staten na hun terugkeer nog van invloed was op de kans op ALS. 
In de vragenlijst werden de naam van de plaatsen en de periode van verblijf buiten de 
Verenigde Staten, mits langer dan een maand, genoteerd. Bij het vergelijken van deze 
gegevens bleek dat de ALS patienten vaker op Guam waren geweest (duur verblijf van 2 
tot 15 maanden) dan de controles. Verblijf op Guam bleef een significante risicofactor voor 
ALS te blijven, ook in de multivariabele analyse met andere mogelijke risicofactoren. 
Deze observatie is in tegenstelling met resultaten van twee eerdere studies, met grotere 
onderzoekspopulaties. In onze studie was de periode tussen het verblijf op Guam en het 
stellen van de diagnose ALS veel langer dan in de twee eerdere studies nl. gemiddeld 43 
jaar ( spreiding 27 tot 57 jaar). 
Hieruit zou de conclusie getrokken kunnen worden dat een van de karakteristieken van  de 
endemische ALS op Guam de lange periode (‘long latency’) was tussen het tijdstip waarop 
de blootstelling heeft plaatsgevonden en het optreden van klinische symptomen. Dit zou 
betekenen dat zelfs een kortdurende verblijf ten tijde van endemische ALS op Guam 
van invloed zou kunnen zijn op de pathogenese van ALS. Wellicht bij personen met een 
specifieke genetische predispositie. Voorts dat het kennelijk heel lang duurde (decennia) 
voor bij deze patienten de klinische symptomen optraden. 
Het tweede deel van hoofdstuk 5 beschrijft onderzoek naar andere omgevings factoren 
die mogelijk, samen met erfelijke factoren, ALS zouden kunnen veroorzaken. In het 
eerder beschreven patient-controle onderzoek werden gegevens over een aantal mogelijk 
schadelijke omgevingsfactoren separaat geanalyseerd. Vervolgens werd voor ieder van deze 
factoren onderzocht of er een interactie was met het effect van een familiegeschiedenis 
voor ALS, dementie of parkinsonisme. Er werden anamnestische gegevens verkregen over 
specifieke infectieziekten, auto-immuun ziekten, operaties en verwondingen, blootstelling 
aan dieren of aan specifieke toxinen (onder anderen: pesticiden, aluminium, lood). Tevens 
werd informatie verzameld over de achtereenvolgende werkzaamheden en beroepen, over 
rookgewoonten en over de consumptie van alcoholische drank. 
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In de multivariabele analyse werd alleen een verband tussen ALS en het gebruik van 
pesticiden en tussen ALS en tuberculose waargenomen. 
De genetisch epidemiologisch analyse in deze studie maakte duidelijk dat onderzoek 
naar een interactie tussen genen en omgevingsfactoren nadere studies vereist met veel 
grotere onderzoekspopulaties om laagsgewijs de invloed van weinig voorkomende 
omgevingsfactoren en de verschillende erfelijke predisposities voor neurodegeneratie in 
sporadische ALS te kunnen analyseren.
De resultaten van dit proefschrift bevestigen de hypothese dat een erfelijke aanleg 
voor ALS als een erfelijke aanleg voor een spectrum van neurodegeneratie kan worden 
beschouwd, in plaats van louter als aanleg voor één specifieke neurologische ziekte. Het is 
van belang hiermee ook rekening te houden bij het erfelijkheidsonderzoek en -advies aan 
de patienten en hun familieleden. In toenemende mate wordt DNA onderzoek mogelijk ter 
bevestiging van de klinische diagnose van neurodegeneratieve ziekten. Ook wanneer DNA 
diagnostiek nog niet mogelijk is, lijkt het zinvol DNA op te laten slaan voor genetische 
diagnostiek in de toekomst.  Van deze kennis kunnen familieleden van de patient later 
voordeel hebben, bijvoorbeeld wanneer er geneesmiddelen of methoden worden ontwikkeld 
om, bij een specifieke aanleg voor neurodegeneratie, het ziekteproces af te remmen of te 
voorkomen.
Het is duidelijk dat een genetische classificatie van ziekten met klinisch overlappende 
kenmerken van ALS, dementie en parkinsonisme het inzicht in de moleculaire pathologie 
van neurodegeneratie zal verdiepen. Er zullen nieuwe genen worden gevonden in families 
waarin ALS, dementie en parkinsonisme samen voorkomen, en dit zal de mogelijkheid 
geven om op moleculair niveau de wisselwerking tussen erfelijke aanleg en bepaalde 
omgevingsfactoren te onderzoeken. Met behulp van die kennis zal er hoepelijk een 
verklaring worden gevonden voor de gevoeligheid van bepaalde groepen neuronen voor een 
degeneratief proces en voor het tijdstip van optreden en de daaropvolgend verloop van de 
pathologie.
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